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his document was developed by the American College of
ardiology Foundation (ACCF) Task Force on Clinical
xpert Consensus Documents (ECDs) and cosponsored by
he American College of Radiology (ACR), American
eart Association (AHA), North American Society for
ardiovascular Imaging (NASCI), and the Society for
ardiovascular Magnetic Resonance (SCMR), to provide a
erspective on the current state of cardiovascular magnetic
esonance (CMR). ECDs are intended to inform practitio-
ers and other interested parties of the opinion of the
CCF and document cosponsors concerning evolving areas
f clinical practice and/or technologies that are widely
vailable or new to the practice community. Topics are
hosen for coverage because the evidence base, the experi-
nce with technology, and/or the clinical practice are not
onsidered sufficiently well developed to be evaluated by the
ormal ACCF/AHA practice guidelines process. Often the
opic is the subject of ongoing investigation. Thus, the
eader should view the ECD as the best attempt of the
CCF and document cosponsors to inform and guide
linical practice in areas where rigorous evidence may not be
vailable or the evidence to date is not widely accepted.
hen feasible, ECDs include indications or contraindica-
ions. Typically, formal recommendations are not provided
n ECDs as these documents do not formally grade the
uality of evidence, and the provision of “Recommenda-
ions” is felt to be more appropriately within the purview of
he ACCF/AHA Practice Guidelines. However, recom-
endations from ACCF/AHA Clinical Practice Guide-
ines and ACCF Appropriate Use Criteria are presented
here pertinent to the discussion. The writing committee is
n agreement with these recommendations. Finally, some
opics covered by ECDs will be addressed subsequently by
he ACCF/AHA Practice Guidelines Committee.
The task force makes every effort to avoid any actual or
otential conflicts of interest that might arise as a result of
n outside relationship or personal interest of a member of
he writing panel. Specifically, all members of the writing
anel are asked to provide disclosure statements of all such
elationships that might be perceived as real or potential
onflicts of interest to inform the writing effort. These
tatements are reviewed by the parent task force, reported
rally to all members of the writing panel at the first
eeting, and updated as changes occur. The relationships
nd industry information for writing committee members
nd peer reviewers are published in Appendix 1 and Ap-
endix 2 of the document, respectively.
Robert A. Harrington, MD, FACC, FAHA
Chair, ACCF Task Force on
Clinical Expert Consensus Documents
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.1. Writing Committee Organization
he writing committee consisted of acknowledged experts
n the field of CMR, as well as a liaison from the ACCF
ask Force on Clinical ECDs, the oversight group for this
ocument. In addition to 2 ACCF members, the writing
ommittee included 1 representative from the American
cademy of Pediatrics (AAP) and 2 representatives from
he ACR, AHA, NASCI, and the SCMR. Representation
y an outside organization does not necessarily imply
ndorsement.
.2. Document Development Process
.2.1. Relationships With Industry
t its first meeting, each member of the writing committee
eported all relationships with industry and other entities
elevant to this document topic. This information was
pdated, if applicable, at the beginning of all subsequent
eetings and full committee conference calls. As noted in
he Preamble, relevant relationships with industry and other
ntities of writing committee members are published in
ppendix 1.
.2.2. Consensus Development
uring the first meeting, the writing committee discussed
he topics to be covered in the document and assigned lead
uthors for each section. Authors conducted literature
earches and drafted their sections of the document outline.
ver a series of meetings and conference calls, the writing
ommittee reviewed each section, discussed document con-
ent, and ultimately arrived at a consensus on a document
hat was sent for external peer review. Following peer
eview, the writing committee chair engaged authors to
ddress reviewer comments and finalize the document for
ocument approval by participating organizations. Of note,
eleconferences were scheduled between the writing com-
ittee chair and members who were not present at the
eetings to ensure consensus on the document.
.2.3. External Peer Review
his document was reviewed by 8 official representatives
rom the ACCF, ACR, AHA, NASCI, and SCMR, as well
s 4 content reviewers, resulting in 279 peer review com-
ents. See list of peer reviewers, affiliations for the review
rocess, and corresponding relationships with industry and
ther entities in Appendix 2. Peer review comments were
ntered into a table and reviewed in detail by the writing
ommittee chair. The chair engaged writing committee
embers to respond to the comments, and the document
as revised to incorporate reviewer comments where
eemed appropriate by the writing committee.
In addition, a member of the ACCF Task Force on
linical ECDs served as lead reviewer for this document.
his person conducted an independent review of the doc- vment at the time of peer review. Once the writing
ommittee documented its response to reviewer comments
nd updated the manuscript, the lead reviewer assessed
hether all peer review issues were handled adequately or
hether there were gaps that required additional review.
he lead reviewer reported to the task force chair that all
omments were handled appropriately and recommended
hat the document go forward to the task force for final
eview and sign-off.
.2.4. Final Writing Committee and Task Force
ign-Off on the Document
he writing committee formally signed off on the final
ocument, as well as the relationships with industry that
ould be published with the document. The ACCF Task
orce on Clinical ECDs also reviewed and formally ap-
roved the document to be sent for organizational approval.
.2.5. Document Approval
he final version of the document along with the peer
eview comments and responses to comments were circu-
ated to the ACCF Board of Trustees for review and
pproval. Several issues arose during board review that were
ddressed by the writing committee. The document was
pproved in November 2009. The document was then sent
o the governing boards of the ACR, AHA, NASCI, and
CMR for endorsement consideration, along with the peer
eview comments/responses for their respective official peer
eviewers. All 4 organizations formally endorsed this docu-
ent. This document will be considered current until the
CCF Task Force on Clinical ECDs revises or withdraws
t from publication.
.3. Purpose of This Expert Consensus Document
his document is the first ACCF/ACR/AHA/NASCI/
CMR Expert Consensus Document on CMR. It serves
he following purposes: 1) it introduces the basic instrumen-
ation, physics, scan techniques, safety parameters, and
ontraindications associated with CMR acquisitions; 2) it
eviews the use of CMR for assessing patients with cardio-
ascular disease processes; and 3) unique capabilities of
mage data generated with CMR are provided relative to
ther imaging techniques. Finally, recommendations from
CCF/AHA clinical practice guidelines and ACCF appro-
riate use criteria are presented where pertinent. In addition,
ew recommendations for the use of CMR in clinical practice
ere developed by this writing committee and are presented
or those situations where guidelines are unavailable.
.4. Document Overview
MR is an imaging modality that provides a mechanism to
ssess cardiac or vascular anatomy, function, perfusion, and
issue characteristics in a highly reproducible manner during
single examination. Images can be acquired in patients ofarious body habitus, in a time-efficient fashion, without an
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odinated intravenous contrast medium.
.5. CMR Physics
MR is based on the detection of signals from hydrogen
uclei which are in very high concentration within the body
approximately 100 M) (1). Upon a patient entering a
canner, hydrogen nuclei align with and “precess” about the
xis of the magnetic field. This precession can be perturbed
y application of additional small magnetic field pulses. By
pplying these pulses in a controlled manner in the form of
pulse sequences,” signals can be received and processed to
roduce an image of the spatial distribution of the spins or
rotons within the body. A unique feature of CMR is the
vailability of multiple types of pulse sequences for imaging
hat can define cardiac structure, characterize tissue, or
easure cardiovascular function.
.6. Magnetic Field Strength
he strength of the magnetic field within the scanner is
easured in Tesla (T) (2). Typical commercially available
MR field strengths for use in patients with cardiovascular
isease are 1.0-, 1.5-, and 3.0-T. In general, images ac-
uired at higher field strengths exhibit proportionally
reater signals, and thus can produce images with higher
patial resolution and more precise delineation of cardiac or
ascular structures. On occasion, however, artifacts become
ore prominent at higher field strengths, which may
ometimes negate the advantage provided by the higher
patial resolution.
.7. Configuration and Instrumentation
ithin the CMR Suite
MR suites are comprised of 5 components: 1) the room
ousing the scanner; 2) the console room used to direct the
canning process; 3) an image interpretation room; 4) a
pace allocated for the preparation and recovery of patients;
nd 5) a technical room for magnet-related equipment. In
ddition to the magnet, accessory equipment for the scan-
ing procedure is also present in the CMR scanner room.
his equipment includes special devices that function in a
igh magnetic field to monitor heart rate and blood pres-
ure, as well as administer intravenous medications or CMR
ontrast agents. The operator console for the scanner is
ocated outside of the scanning room. This master console is
tilized by the technologist or physician to direct image
cquisition, implement pulse sequences, and to display
mages for immediate review after acquisition. Once images
re acquired, they are often transferred to other computer
orkstations for the purpose of image analysis, storage, and
hysician review.
.8. Advantages of CMR
MR possesses several advantages for the study of patients
ith cardiovascular disease (3). First, images are acquired
ithout application of ionizing radiation or the administra-ion of radioactive isotopes or iodinated contrast. The toninvasive acquisition of images without the use of ioniz-
ng radiation facilitates the diagnosis and subsequent mon-
toring of medical conditions without incurring the risk of
eveloping conditions related to ionizing radiation expo-
ure. Second, CMR images can be acquired throughout the
ody in any tomographic plane without limitations imposed
y body habitus. This feature can be helpful in patients with
coustic window limitations during transthoracic echo-
ardiography or attenuation artifacts during radionuclide
cintigraphy.
Third, CMR is a flexible imaging modality that allows
ssessment of multiple different parameters of cardiovascu-
ar anatomy and function. As mentioned, CMR can define
ardiovascular anatomy and structure, characterize tissue
omposition (including myocardial viability), measure func-
ion in terms of heart wall motion or blood flow, assess
etabolism with spectroscopic techniques, visualize and
uantify myocardial perfusion, and define the course and
rientation of epicardial coronary arteries. Importantly,
ecent advances allow for the acquisition of this type of
nformation throughout the body; thus, the ability exists to
recisely define cardiovascular phenotype in patients with
isease processes such as atherosclerosis, cardiomyopathies,
iabetes, and hypertension that commonly affect individuals
ith cardiovascular disease (3).
A fourth advantage of CMR imaging is the ability to
uantify with relatively high spatial and temporal resolution
eaningful measures of cardiovascular structure or perfor-
ance that discriminate normal from abnormal pathologic
onditions or denote adverse cardiovascular prognoses (3).
t 1.5-T, voxel sizes of 1  1  3 cm can be acquired with
ost pulse sequence strategies. When cine sequences are
equired, frame rates of 20 to 40 ms are routinely available
llowing for the characterization of time-dependent pro-
esses such as left ventricular (LV) diastolic function.
easurements of myocardial mass; blood flow through
essels or across valves; LV or right ventricular (RV)
yocardial thickening, strain, or tissue perfusion; infarct
ize; or plaque burden can be quantified in absolute terms.
tudies have confirmed high reproducibility and low vari-
nce of these measures in repeated samples indicating
arked precision of CMR for use in clinical or research
xaminations (4).
. Assessment of Cardiovascular Structure
nd Function With CMR
.1. Dimension and Morphology
.1.1. Dark Blood Imaging
ark blood imaging sequences, for example those acquired
ith spin echo or inversion recovery techniques, are used to
cquire morphologic images of the heart (5–8). In these
echniques, protons in nonmoving or slowly moving struc-
ures such as the myocardium provide high signal in the
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reat vessels moves out of the imaging slice (and are
herefore not exposed to both of the radiofrequency pulses),
esulting in a signal void (hence the term “dark blood”).
Dark blood imaging strategies are used throughout the
pectrum of cardiovascular diseases, including the assess-
ent of cardiac and great vessel morphology in congenital
eart disease and thoracic aortic disease (9–11), the assess-
ent of myocardial masses, and the evaluation of the
ericardium (12–14).
.1.2. Bright Blood Imaging
right blood imaging is advantageous for acquiring high
emporal resolution cine movies of LV and RV systolic and
iastolic function. Imaging strategies include gradient echo
GRE), segmented k-space GRE, GRE hybridized with an
cho-planar readout, and steady-state free precession
SSFP) techniques. These sequences produce images in
hich the blood pool is bright relative to the adjacent
ntermediate signal intensity of the myocardium. These
echniques can also be used to identify intravoxel dephasing
elated to turbulent blood flow from valvular stenosis or
egurgitation (15).
Cine CMR for evaluation of cardiac volumes and systolic
unction is considered a standard of reference by which
ther modalities are validated (7). This includes normal
hysiology such as atrial or right-sided myocardial assess-
ent, as well as pathological conditions with low flow states
uch as congestive heart failure.
.2. Myocardial Function
MR is an accurate and highly reproducible technique for
easuring ejection fraction and ventricular volumes in 3
imensions (16). Unlike 2-dimensional (2D) projection tech-
iques, cine CMR imaging does not rely on geometric as-
umptions or calculations based on incomplete sampling of the
ardiac volumes (17–19). Newer SSFP techniques have largely
eplaced conventional GRE for cine CMR assessment of
yocardial volumes, mass, and systolic function (20,21). An
ffset exists between the older conventional GRE techniques
nd SSFP cine-generated CMR measures. The offset between
olumes and mass between the 2 CMR methods is linear over
he range of interest, so that normal databases for myocardial
unction may be adapted for the newer SSFP cine CMR
ethod (22).
For CMR measurement of myocardial volume and mass,
onsecutive breath-hold short axis 6- to 10-mm tomo-
raphic cine short-axis cross-sections of the heart are
btained; the summation of discs method is then applied to
etermine the total myocardial mass and volume (3). A
eries of long-axis views rotated around the anatomical axis
f the left ventricle can also be used to assess LV function
ith comparable accuracy (23–25). In a typical application,
he temporal resolution of cine CMR for myocardial func-
ion determination is 50 ms or less. Breath-hold time for
ach cross-sectional slice is approximately 5 to 10 seconds; mhe lower imaging times are achieved with newer CMR
canners that use parallel imaging techniques. For myocar-
ial mass, the total volume of the myocardial wall at
nd-diastole is multiplied by the specific gravity of the
yocardium (1.05 g/mm3). Myocardial mass and ventricu-
ar volumes are commonly adjusted for body size by dividing
aw measures by body surface area to derive indexed values.
ingle acquisition, 3-dimensional (3D) CMR acquisition
ethods for the heart are available. The temporal resolution
n thin, relatively new acquisition is typically lower (100 ms)
han the slice-by-slice acquisition methods; spatial resolu-
ion is lower as well. The primary advantage is a single
reath-hold of 20 to 30 seconds to cover the entire myo-
ardium in this cine 3D mode.
A significant advantage of CMR for evaluation of myo-
ardial mass and volume is its reproducibility and accuracy
ompared with 2D planar or projection techniques that
epend on geometric assumptions in order to define mass
nd volume determinations. As a result, small changes in
yocardial mass and/or volume can be detected over time or
s a result of therapy. This is particularly useful for deter-
ining the impact of therapy or for research purposes in
linical trials where sample size can be reduced by an order
f magnitude compared with planar or projection tech-
iques using LV geometric assumptions (26,27). CMR LV
ize and systolic function are precisely determined with
tandard errors of about 5% (16,19,28–30).
Using CMR, normal LV volumes and mass have been
etermined to be smaller for women than men even after
djustment for body size (16). In normal individuals, LV mass
s relatively constant with increasing age in adults, although LV
olumes decrease by about 3% per decade from age 45 years.
sian-American men tend to have slightly smaller body
ize–adjusted LV mass and volumes (5%) compared with
hites, African-Americans, and Hispanics.
Regional myocardial function may be assessed using CMR
agging (31,32). In this method, specialized radiofrequency
ulses are applied prior to the beginning of the cine CMR
ulses sequence. These additional pulses result in alteration of
he magnetic properties of the heart, typically in a grid stripe
attern. The grids or stripes are dark relative to the remaining
yocardium, and the grids are displaced as a result of myo-
ardial motion/contraction. For research purposes, specialized
oftware is available for dynamic analysis of the spacing
etween the magnetic stripes, allowing regional myocardial
train to be calculated. CMR tagging has allowed precise
uantification of regional heterogeneity in myocardial contrac-
ion in the setting of coronary artery disease (CAD) and
onischemic cardiomyopathy (33–36). In clinical practice,
MR tagging is most commonly interpreted qualitatively
ather than quantitatively. New methods (DENSE [displace-
ent encoding with stimulated echoes in CMR] [37] and
ARP [harmonic phase] [38]) may offer more automated
ethods for myocardial strain analysis.
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MR can be used to assess myocardial metabolism without
he need for administration of radioactive tracers; the basis
or the assessment of myocardial metabolism is magnetic
esonance spectroscopy. For spectroscopy, nuclei other than
ydrogen may be studied, but there are substantial scanner
ardware modifications and signal-to-noise compromises
nvolved in using other nuclei. At the time of writing,
linical cardiac spectroscopy is not available as a routine
ool. Spectroscopic approaches have been applied to evaluate
he behavior of the high-energy phosphates; phosphorus-31
rovides the basis for such evaluation (39). The spectrum is
epresented by a series of peaks, each of which represents 1
r more molecular species, including adenosine triphosphate
ATP), phosphocreatine (PCr), and inorganic phosphate.
he position of a spectral peak is determined by the
henomenon of chemical shift, which is related to the
hemical nature and environment of the molecule. For
xample, the position of or chemical shift of the inorganic
hosphate peak is related to the intracellular pH. With
schemia, the environment becomes acidic, and the inor-
anic phosphate peak is shifted to the right. Due to the
elatively low concentration of 31P, a large volume of
yocardium (20 to 30 cm3) must be interrogated to gener-
te a 31P spectrum at 1.5-T. Spectral resolution can be
mproved by using a higher field strength, for example,
.0-T, and thus, 3.0-T is often preferred.
.4. Phase-Contrast Blood Flow
n addition to the magnitude data used to generate cine
MR images of cardiac function, the phase data collected
rom the image acquisition can be used to measure velocity
40). The use of the phase data, termed the “phase-contrast”
PC) technique, relies on the fact that blood flowing
hrough a magnetic field gradient produces a phase shift
hat is proportional to the velocity of flow (41). By summing
he PC-generated velocities within the area of the lumen
hroughout the cardiac cycle, blood flow within the vessel
an be calculated. PC-CMR measures of blood flow agree
trongly with those obtained in phantom models as well as
y both noninvasive and other accepted invasive techniques
42,43). Conventional PC magnetic resonance (MR) usu-
lly encodes the velocity in a single direction. More recently
eveloped tridirectional PC MR allows velocity encoding in
ultiple directions, facilitating direct visualization of flow
isturbances such as vortices or turbulent flow (44).
Clinically, PC-CMR measures of blood flow velocity
ave been acquired in the aorta (43), the pulmonary arteries
45), coronary artery bypass grafts (46), and across heart
alves (47). These data are useful for identifying abnormal-
ties of blood flow in patients with diseases of the aorta
aortic dissection, aneurysms, or coarctation) (46), congen-
tal heart disease (either through native vessels or surgically
laced conduits) (48,49), or stenotic/regurgitant valveesions (3). s.5. Myocardial Perfusion
yocardial perfusion imaging by CMR is most commonly
chieved with rapid dynamic imaging during the first pass of
tracer or contrast agent (50). Coronary autoregulation
rovides an efficient mechanism for maintaining adequate
yocardial blood flow during resting conditions in the
resence of flow-limiting epicardial lesions. However, dur-
ng stress, myocardial perfusion is inadequate in the setting
f flow-limiting epicardial coronary artery stenoses. The
yocardial perfusion examination therefore consists of a
easurement at baseline (rest) and a comparative measure-
ent during stress. The term stress is used here in a generic
orm, and in most cases, a vasodilator is administered to
nduce maximal hyperemia and determine the coronary flow
apacitance. The pharmacological agents that are most
idely used for myocardial perfusion imaging with CMR
nclude adenosine and dipyridamole. Exercise-induced
tress is currently performed in specialized academic centers.
Contrast agents used for CMR generally reduce both the
ongitudinal (T1) and transverse (T2) relaxation times (51).
ulse sequence techniques sensitive to T1, T2, or both can
e employed to detect the transit of contrast agent through
perfusion bed. Currently, myocardial perfusion studies are
ostly based on T1-weighted 2D, multislice imaging, with
to 5 slices being considered the minimum for coverage of
he heart. As an alternative to vasodilator perfusion imag-
ng, dobutamine can be administered for assessment of
egional contractile response during rest and stress condi-
ions. Recent data on the prognostic value of CMR perfu-
ion imaging indicate that patients with a normal myocar-
ial vasodilator perfusion reserve and normal dobutamine
tress (DS) wall motion have a 3-year event-free survival
ate of 99.2% (52).
In patients with suspected coronary disease, myocardial
erfusion reserve measured by CMR yields high diagnostic
ccuracy for the detection of flow-limiting lesions (53–55).
MR perfusion imaging has also been used to assess
unctional improvements after percutaneous coronary inter-
entions (56–58). Microvascular dysfunction and microvas-
ular obstruction after myocardial infarction are detected by
MR (59,60), and the presence of microvascular obstruc-
ion detected by early hypoenhancement carries valuable
rognostic information, independent of infarct size
61–63). The extent and incidence of microvascular ob-
truction observed with CMR has been associated with the
uration of ischemia before coronary intervention (64).
An international, multicenter study demonstrated that
MR perfusion imaging exhibits high specificity for
etecting coronary disease (65). Other single-center
tudies have shown similar findings (66). High spatial
esolution provides high utility for detecting flow deficits
ithin the subendocardium layer (66 – 68), the portion of
he ventricular wall most vulnerable to any flow reduc-
ions. CMR perfusion imaging, by virtue of its excellent
patial resolution, may also be indicated in pediatric
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articular concern (69).
.6. Angiography
agnetic resonance angiography (MRA) exhibits benefits
elated to its lack of exposure to ionizing radiation, iodin-
ted contrast agents, or arterial access (70–72). Moreover,
RA image acquisitions are typically 3D and afford im-
roved visualization of complex geometries through image
ostprocessing of maximum intensity projection and multi-
lanar reformations of 3D data sets. MRA techniques
xhibit high utility for assessing the carotid arteries, aorta,
enal arteries, and peripheral vasculature.
CMR offers a variety of methods for visualizing vascular
athology. Conventional T1- and T2-weighted dark blood
echniques (e.g., spin echo, fast spin echo, and double
nversion recovery fast spin echo) enable proper depiction of
essel walls (73). Bright blood imaging techniques (Table 1;
ime-of-flight, phase contrast, SSFP, and contrast-enhanced
agnetic resonance angiography [CE-MRA]) provide the
bility to evaluate blood flow and to generate images of
essel lumens that allow selective display of vascular anat-
my in 3D projections. With improvements in scanner
peed, it is now possible to perform rapid frame rate MRA,
lso known as time-resolved MR angiography, allowing
irect visualization of flow dynamics, which may be impor-
ant for assessment of vascular shunts or dissections.
.7. Tissue Characterization
unique feature of CMR is the ability to use characteristics
f proton relaxation, typically referred to as the relaxation
imes T1, T2, and T2*, to characterize myocardial or
ascular tissue. Whereas T1 images are often used for
ontrast-enhanced studies (see the following text), T2 and
2* imaging mostly have been used in noncontrast ap-
roaches. For example, within the myocardium, T2-
eighted CMR imaging is sensitive to regional or global
ncreases of myocardial water content. Increased myocardial
ater content has been shown in acute heart diseases such as
ransplant rejection, acute myocarditis, and acute myocar-
ial infarction (74) (Figure 1A).
Another noncontrast tissue characterization technique
elates to the T2* relaxation of the tissue. T2* times are
ignificantly altered by the myocardial iron content; their
uantification provides an excellent marker for iron overload
see Section 3.5.8, Hemochromatosis).
Contrast agents such as gadolinium (Gd) chelates shorten
he T1 relaxation time within the surrounding tissue and
ncrease the signal intensity of regions with high Gd
oncentration during T1-weighted imaging. In essence, Gd
helates facilitate water visualization in the intravascular
blood) or in the extravascular organ tissue space. This can
e used to selectively identify areas with reduced or in-
reased “uptake” of Gd (Figure 1B). Regional differences of
d inflow characteristics after intravenous injection (“first-ass imaging”) can be used to assess myocardial perfusion. (1-weighted sequences with 3 to 5 slices per heartbeat have
een used in the diagnostic workup for CAD with a very
igh negative-predictive value (52,75). Early after the first
ass of Gd, a significant fraction of the injected Gd enters
he interstitial space. Several minutes after intravenous
dministration of Gd, the larger volume of distribution
vailable in necrotic or fibrotic myocardium results in a
igher concentration of contrast agent than what is present
n viable myocardium. This is typically referred to as
delayed (hyper)enhancement” or “late gadolinium en-
ancement” (LGE) (76). The transmural extent of myocar-
ial scars as defined by LGE predicts functional recovery
fter revascularization (77) and is related to prognosis (78).
Patterns other than the endocardial accumulation of
GE can occur. For example, LV epicardial and midwall
nhancement are known to be associated with infectious
auses of myocardial inflammation (Figure 1C). Also, in-
ammatory conditions involving the heart, such as with
arcoidosis, are associated with midwall accumulation of
GE. A special mechanism may be the cause for Gd
ccumulation in cardiac amyloidosis. Data indicate that a
olecular binding of Gd to amyloid may lead to the
xtensive uptake of the agent in myocardial tissue, typically
ssociated with a very rapid washout from blood (79).
. Important Applications
.1. Heart Failure
MR may be used for assessment of LV and RV size and
orphology, systolic and diastolic function, and for
haracterizing myocardial tissue for the purpose of un-
erstanding the etiology of LV systolic or diastolic
ysfunction. The writing committee recognizes the po-
ential capabilities of spectroscopic techniques for ac-
uiring metabolic information of the heart when evalu-
ting individuals with heart failure.
When assessing patients with heart failure, CMR is
seful in several aspects (80). Questions that may be
nswered by CMR include understanding of the presence
nd severity of morphological and functional abnormalities
f the LV or RV myocardium, determining the underlying
tiology (e.g., ischemic versus nonischemic disease) of LV
r RV dysfunction, and identifying prognostic factors re-
ated to patient outcomes. Often, follow-up studies are
equired during or after therapeutic interventions. CMR
ffers more accurate assessment of function and morphology
han most available imaging modalities, providing reliable
olumetric data with high diagnostic image quality in nearly
ll patients. Table 2 displays quantitative and qualitative
arameters, each of which can be used as diagnostic markers
r descriptors in patients with suspected heart failure.
In general, cine SSFP sequences are used to visualize and
uantify global left and right atrial and ventricular systolic
unction with reference data sets for normal subjects
16,81,86). Regional LV and RV systolic function can be
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Target of Evaluation Technique Description Advantage Common Clinical Indication(s)
imension and
morphology
SE and double IR
GRE/SSFP (not cine)
“Dark blood”
“Bright blood”
● Vessel and myocardial wall evaluation
● Less sensitive to motion artifact than
dark blood SE
● LV dimensions, relationships
of heart to other structures in
chest
● Myocardial masses,
pericardial disease
● Aortic dimensions and
internal lesions, including
intimal flap of dissection
unction Cine SSFP (1.5-T)
or cine GRE (higher
field strengths;
e.g., 3.0-T)
Tissue tagging
“Bright blood” cine with
temporal resolution of
30–60 ms
● High temporal resolution
● Relatively flow-independent
● 2D and 3D high accuracy and
reproducibility
● LV and RV volumes and
ejection fraction, such as in
heart failure
● LV and RV regional wall
motion
● Valvular heart disease
● With tagging, useful for
quantifying LV and RV systolic
and diastolic function
etabolism MR spectroscopy
with 31P
Detection of spectral peaks
for 31P metabolites
● High specificity ● Ischemia evaluation
lood flow velocity Phase-contrast imaging Blood velocity leads to phase
shift displayed on gray
scale
● High accuracy
● Velocity and flow quantitation
● Locating and identifying intracardiac
shunts or valvular lesions
● Valvular poststenotic and
regurgitant flow
● Large (aorta) and medium
(renal, femoral, carotid)
arterial flow
● Pulmonary artery and vein
blood flow
● Qp/Qs (intracardiac shunts)
● Determination of true and
false lumen blood flow
erfusion T1-sensitive sequences,
single-shot, multislice
acquisitions w/GRE
or GRE-EPI hybrid
sequences
Contrast-based first-pass
imaging for detection of
hypoperfused myocardial
segments
● High spatial resolution (2 mm
in-plane)
● Rapid results
● Ischemia evaluation,
including detection of CAD
under stress
● Microvascular disease
ngiography Noncontrast MRA (e.g.,
TOF, proximal
compression, SSFP)
Relies on blood flow (TOF and
proximal compression) or
T2/T1 ratio (SSFP)
● No contrast required ● Coronary artery angiography
for detection of stenosis or
anomalous origin/course
3D CE-MRA T1 shortening with contrast-
enhanced MRA image
● Fast and reliably provides
“luminogram” for most vascular
territories
● Bypass graft stenosis
● Aortography
● Carotid angiography
● Renal angiography
● Peripheral angiography
issue Noncontrast
characterization T1-weighted spin echo Fat has very high signal
intensity
● Sensitive for increased fat content ● ARVC/D
● Cardiac mass
T2-weighted spin echo Low signal-to-noise ratio, but
very sensitive to edema
● Sensitive for increased water content ● Acute infarction
● Acute myocarditis
T2*-weighted
sequences
Iron leads to T2* shortening,
quantitative evaluation is
required
● Sensitive for iron ● Hemochromatosis
Contrast-based
T1-weighted spin echo Early enhancement reflects
hyperemia and capillary
leak
● Inflammation ● Myocarditis
● Acute MI
T1-weighted/inversion
recovery
Late enhancement
Late enhancement reflects
areas with delayed wash
out of gadolinium
● Sensitive for necrosis, fibrosis, and
myocardial amyloid
● MI
● Myocarditis
● Infiltrative disease
(e.g., amyloid, sarcoid)
● Hypertrophic or eosinophilic
cardiomyopathy
D indicates 2-dimensional; 3D, 3-dimensional; ARVC/D, arrhythmogenic right ventricular cardiomyopathy/dysplasia; CAD, coronary artery disease; CE-MRA, contrast-enhanced magnetic resonance
ngiography; GRE, gradient echo; GRE-EPI, gradient echotype planar imaging; IR, inversion recovery; LV, left ventricular; MI, myocardial infarction; MR, magnetic resonance; Qp/Qs, pulmonary to systemic
ow ratio; RV, right ventricular; SE, spin echo; SSFP, steady state free precession; T, Tesla; and TOF, time-of-flight.
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic Resonancessessed in great detail using myocardial tagging, with circum-
erential strain the most widely described parameter (82,87).
Diastolic LV function has also been assessed with CMR.
or this purpose, analogous echocardiographic parameters
igure 1. Cardiovascular Magnetic Resonance of Acute Myocardit
anel A: T2-weighted image of LV myocardial edema showing global bright signal inte
ent (T1-weighted spin echo) before (left) and after (right) Gd administration; enhan
cho sequence with myocardial nulling) 10 minutes after Gd. Gd indicates gadolinium
able 2. Cardiovascular Magnetic Resonance–Derived Paramet
Parameters
ystolic function LV and RV end-diastolic volumes and indices
LV and RV end-systolic volumes and indices
LV and RV stroke volume and index
LV and RV ejection fraction
Cardiac output and cardiac index
Regional and global systolic wall thickening
Regional or global measures of myocardial s
orphology LV mass and indices
Mean and maximum myocardial wall thickne
Assessment of pericardium
all stress End-systolic wall stress
iastolic function Circumferential strain and strain rate
Peak untwisting rate
End-diastolic forward flow in pulmonary veins
E/A ratio
eversible acute injury Edema (regional or global high signal intensi
T2-weighted images)
rreversible injury, prognosis Myocardial fibrosis (late enhancement)SA indicates body surface area; E/A, early/atrial (late) ratio for ventricular filling; LV, left ventricular;uch as transmitral flow pattern or the presence of end-
iastolic pulmonary vein forward flow can be utilized (83).
n addition, CMR provides approaches for quantifying LV
yocardial tissue velocity and strain/strain rates. Indicating
(ratio 2.2) of the left ventricle relative to the myocardium. Panel B: Early enhance-
t ratio 5.4. Panel C: Arrows indicating late enhancement (T1-weighted gradient
LV, left ventricular.
n Patients With Suspected Heart Failure
Acronym Units Reference
LVEDV(I), RVEDV(I), mL, mL/cmheight, mL/m
2
BSA (16,79,81)
LVESV(I), RVESV(I) mL, mL/cmheight, mL/m
2
BSA
LVSV(I), RVSV(I) mL, mL/cmheight, mL/m
2
BSA
LVEF, RVEF %
CO, CI mL/min, mL/min/m2BSA
%
Ecc (%), (%)/s
LVM g, g/cmheight, g/m
2
BSA (16,79,81)
MWT mm
mm
ESWS N/m2  1000 (30)
Ecc (%), (%)/s (82)
°/s
E/A, Ea (83)
(84)
% of LV mass or myocardial
segment
(85)is
nsity
cemeners i
train
ss
ty inN, Newton; and RV, right ventricular.
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Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62ts usefulness, strain analysis has been used for detecting
egional abnormalities in patients with LV hypertrophy
espite normal systolic function and lack of clinical evidence
or heart disease (33).
CMR may also provide important information regarding
issue abnormalities (see Section 2.7, Tissue Characteriza-
ion). Focal fibrosis defined by LGE has provided novel
nsights into etiology and risk assessment of patients with
V dysfunction. Of great importance, the regional distri-
ution of scarring allows an accurate discrimination of
schemic from nonischemic cardiomyopathies (88). In con-
rast to subendocardial involvement, patients with nonis-
hemic etiologies of heart failure either do not have detect-
ble focal scars or have a nonsubendocardial distribution
hat is very distinct from ischemic subendocardial and
ransmural patterns. Even within the group of nonischemic
ardiomyopathies, the regional distribution may help to
dentify the underlying etiology. In hypertrophic cardiomy-
pathy (HCM), the LGE is typically found in hypertro-
hied regions and in the interventricular septum close to the
V insertion areas. In dilated cardiomyopathy, an intramu-
al layer of septal fibrosis has been described as a typical
eature and is of strong prognostic value (85,89). Typical
egional patterns of LGE in various etiologies have been
eviewed elsewhere (90).
In patients with acute heart failure, T2-weighted CMR
ay be useful to detect myocardial inflammation due to
cute myocarditis (91). In cardiac iron overload, quantifica-
ion of T2* relaxation times (92) have proven useful for
stimating intramyocardial iron content.
Abnormal high-energy phosphate metabolism has been
tudied by 31P-CMR spectroscopy in patients with dilated
ardiomyopathy (93) and HCM (94). 31P-CMR spectros-
opy, however, is limited by a strong signal from water-
ound protons and difficulties in spectral interpretation due
o the weak 31P signal. Due to these limitations, 31P-CMR
pectroscopy does not yet have a clinical role in the
anagement of heart failure.
.1.1. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR measurements of biventricular function and volumes
re highly reproducibile, accurate, and can be acquired with
high temporal resolution, thereby allowing precise iden-
ification of the point in time in which end-systole and
nd-diastole occurs. High precision and avoidance of ion-
zing radiation allows CMR to be used in longitudinal serial
valuations of patients with heart failure and to assess
esponse to medical intervention or to evaluate disease
rogression (26,95). Furthermore, CMR has unique ap-
roaches to visualize tissue pathology, such as fibrosis, and
herefore provides important diagnostic information. Im-
ortantly, CMR is highly advantageous in patients that may
ave body habitus limitations with other imaging tech-
iques (i.e., acoustic window limitations or attenuation
rtifacts). t.1.2. Summary of Existing Guidelines and
ppropriate Use Criteria
he ACC/AHA 2005 Guideline Update for the Diagnosis
nd Management of Chronic Heart Failure in the Adult
ndicates that CMR may be useful in evaluating chamber
ize and ventricular mass, as well as assessing cardiac
unction and wall motion (96). CMR may also be used to
dentify myocardial viability and scar tissue in patients with
eart failure. CMR of the heart or liver may be useful for
onfirming the presence of iron overload (96).
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging lists CMR evaluation of LV function as an
ppropriate indication in heart failure patients or those with
echnically limited echocardiograms (97).
.2. Coronary Artery Disease
MR may be useful for identifying coronary artery
nomalies and aneurysms, and for determining coronary
rtery patency. In specialized centers, CMR may be
tilized to identify patients with multivessel CAD with-
ut exposure to ionizing radiation or iodinated contrast
edium.
Over the past decade, CMR has evolved into an impor-
ant diagnostic modality for patients with suspected anom-
lous CAD and coronary artery aneurysms. In specialized
cademic centers of excellence, CMR has reached sufficient
aturity for discrimination of patients with multivessel
AD. This may be especially helpful among patients
resenting with a dilated cardiomyopathy in the absence of
clinical history of myocardial infarction.
Coronary CMR is more technically challenging than
MR of other vascular beds due to several unique issues
ncluding: the small caliber of the coronary arteries (3- to
-mm diameter), the near constant motion of the coronary
rteries (during both the respiratory and the cardiac cycles),
he high level of tortuosity of the coronary arteries, and the
urrounding signal from adjacent epicardial fat and myocar-
ium (98–105). To overcome these obstacles, CMR ap-
roaches employ 1) cardiac triggering (e.g., vector electro-
ardiogram [ECG]) to suppress bulk cardiac motion; 2)
espiratory motion suppression (e.g., breath-hold, CMR
avigators); 3) prepulses to enhance contrast-to-noise ratio
f the coronary arterial blood (e.g., fat saturation, T2
reparation); and 4) 3D acquisition that offers superior
ostprocessing capabilities. Bright blood (segmented
-space GRE and SSFP) are most commonly used without
n exogenous contrast agent (e.g., Gd diethylene triamine
entaacetic acid). A special consideration in this popula-
ion is intracoronary stents (see Section 4, CMR Safety),
hich are generally CMR compatible but demonstrate a
ocal signal void/image distortion that is dependent on both
he stent material and the CMR sequence, thereby preclud-
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic Resonanceng direct evaluation of intrastent and peristent coronary
ntegrity.
.2.1. Anomalous Coronary Artery Identification
lthough unusual (less than 1% of the general population
106]) and usually benign, congenital coronary anomalies in
hich the anomalous segment courses between the aorta
nd pulmonary artery are a well-recognized cause of myo-
ardial ischemia and sudden cardiac death, especially among
oung adults (99). Catheter-based X-ray angiography has
raditionally been the diagnostic imaging test to identify
hese anomalies, but the presence of an anomalous vessel is
ometimes only suspected after the procedure, particularly in
situation where there was unsuccessful engagement or
isualization of a coronary artery.
.2.2. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR has several advantages for diagnosing coronary artery
nomalies. CMR does not require ionizing radiation (likely
o be an important consideration among adolescents and
ounger adults with suspected anomalous CAD) or iodin-
ted contrast agents. Both 2D breath-hold and targeted 3D
r whole-heart free-breathing navigator coronary CMR meth-
ds have been used with similar excellent results (Table 3),
Figures 2 and 3) (98,100–105), including several instances
n which the 3D aspects of coronary CMR were of marked
tility relative to 2D projection techniques (Table 3). The
se of coronary CMR for suspected anomalous coronary
isease is also very helpful when an intramural course is
uspected or present (107).
.2.3. Coronary Artery Aneurysms
n the absence of a percutaneous intervention, the vast
ajority of acquired coronary aneurysms are due to muco-
utaneous lymph node syndrome (Kawasaki’s disease).
hese aneurysms are the source of both short- and
ong-term morbidity and mortality (108). Coronary CMR
Figure 4) studies have confirmed the high accuracy of
oronary CMR for both the identification and the charac-
erization (diameter/length) of these aneurysms (109–111).
imilar data have been reported for ectatic coronary arteries
able 3. CMR Identification of Anomalous Coronary Vessels
Investigators
(Reference) n
Correctly Classified
Anomalous Vessels
cConnell et al. (101) 15 14 (93%)
ost et al. (102) 19 19 (100%)*
liegen et al. (105) 12 11 (92%)†
aylor et al. (104) 25 24 (96%)
unce et al. (98) 26 26 (100%)‡
Includes 3 patients originally misclassified by X-ray angiography. †Includes 5 patients unable to
e classified by X-ray angiography. ‡Includes 11 patients unable to be classified by X-ray
ngiography.nd fistulas (112).
h
t.2.4. Coronary CMR for Identification of
ative Vessel Coronary Stenoses
ata regarding the clinical utility of coronary CMR for
ative vessel integrity are based on high-risk populations
eferred for X-ray angiography. No data are available
igure 2. Cardiovascular Magnetic Resonance of a
oronary Artery Anomaly
n oblique axial reconstruction is presented from a “whole-heart coronary MRA”
equence. The white arrow notes the normally arising left main coronary artery from
he left sinus of Valsalva. The black arrowhead highlights the right coronary artery
rising anomalously from the anterior aspect of the left sinus of Valsalva superior
o the left main origin and then coursing between the aortic root and the outflow
ract of the right ventricle. MRA indicates magnetic resonance angiography.
igure 3. Cardiovascular Magnetic Resonance of a
ingle Coronary Artery
3-dimensional volume-rendered reconstruction from a “whole-heart coronary
RA” sequence in a patient with single ventricle and a single coronary artery. The
hite arrow denotes the proximal right coronary artery, whereas the black arrow
ighlights the elongated left main coronary artery arising from a common origin with
he right coronary artery. MRA indicates magnetic resonance angiography.
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Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62egarding the use of coronary CMR for patients presenting
ith chest pain or for screening purposes of even high-risk
atients. In addition, the majority of CMR data has been
enerated in a few highly specialized centers.
Using modern free-breathing, navigator-gated 3D-
egmented GRE methods, good results have been shown,
specially for the proximal coronary segments and in subjects
ith high image quality scans (Table 4) (113–123). Focal
isease is depicted as local signal attenuation. An international
ulticenter, free-breathing, 3D volume-targeted coronary
igure 4. Cardiovascular Magnetic Resonance of a
roximal Aneurysm
ransverse targeted 3-dimensional T2 prepulse coronary MRA of a subject with a
roximal right coronary artery aneurysm. Ao indicates aorta; L, left coronary artery;
nd MRA, magnetic resonance angiography.
able 4. Free-Breathing 3D Gradient Echo Coronary CMR Using
ocal >50% Diameter Coronary Stenoses
Investigators
(Reference) n Techn
rospective navigators with real-time correction-targeted 3D
Bunce et al. (98)* 34
Sommer et al. (123)† 112
Bogaert et al. (113) 19
Dewey et al. (115) 15‡ SS
Maintz et al. (119) TF
SS
Ozgun et al. (120) 20 SS
Jahnke et al. (116) 21 SS
rospective navigators with real-time correction whole-heart SSFP
Sakuma et al. (121) 101
Jahnke et al. (117) 55
Sakuma et al. (122) 106
Kim et al. (118) 109
D indicates 3-dimensional; CMR, cardiovascular magnetic resonance; LM/3VD, left main coro
*Excludes 5 patients for “lack of cooperation” and 15 segments for being uninterpretable. †Based
ree breathing CMR images.MR study of patients without prior X-ray angiography using
ommon hardware and software demonstrated a very high
ensitivity (100%) and modestly high specificity (85%) with
ery high negative-predictive value (100%) of coronary CMR
or the identification of left main and multivessel CAD
greater than or equal to 50% diameter stenosis by quantitative
oronary angiography) (Table 4) (118). The results were not as
seful for identifying single-vessel disease. Accordingly, coro-
ary CMR is especially valuable for patients who present with
dilated cardiomyopathy in the absence of clinical infarction.
ata suggest it is useful and can supplement LGE methods for
etermining the underlying etiology (ischemic versus nonisch-
mic) of the cardiomyopathy (124).
Increasing data are now available on whole-heart SSFP
oronary CMR methods. Although the technique utilizes an
nferior in-plane spatial resolution, data appear to be at least as
ccurate as free-breathing methods (Table 4) (117,121,122).
his type of data may be useful in heavily calcified lesions
107). Coronary MRA may also be useful for assessing heavily
alcified arteries on computed tomography where blooming
rtifact may obscure the vessel lumen (125).
.2.5. Coronary CMR for Coronary Artery Bypass Graft
ssessment
n comparison with the native coronary arteries, reverse
aphenous vein and internal mammary artery grafts are
elatively easy to image due to their minimal motion during
he cardiac and respiratory cycles and the larger lumen of
everse saphenous vein grafts. With schematic knowledge of
he origin and touchdown site of each graft, a variety of
MR sequences have been used to identify graft patency
126–131).
spective Navigators for Identification of
For >50% Diameter Stenosis
Sensitivity (%) Specificity (%)
88 72
74 63
88 (good quality) 91 (good quality)
85–92 50–83
86 98
92 67
81 82
82 82
79 91
82 91
78 91
82 90
93 (patient) 59 (patient)
100 (LM/3VD) 85 (LM/3VD)
ery or 3-vessel disease; SSFP, steady-state free precession; and TFE, turbo fast-echo.Pro
ique
FP
E
FP
FP
FP
nary art
on 74% of coronary artery segments analyzable by CMR. ‡Based on 60% of patients with good
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic ResonanceLimitations of coronary CMR bypass graft assessment
nclude difficulties related to local signal loss/artifact due to
mplanted metallic objects (hemostatic clips, ostial stainless
teel graft markers, sternal wires, coexistent prosthetic valves
nd supporting struts or rings, and graft stents). Imaging
trategies used to image coronary arteries have also been
pplied to saphenous vein grafts (132) and reported to be
uite accurate for assessment of saphenous vein graft steno-
es, with very good agreement between quantitative X-ray
ngiography for assessment of both graft occlusion (sensi-
ivity 83% [36% to 100%]; specificity 100% [92% to 100%])
nd graft stenosis (greater than or equal to 50%; sensitivity
2% [57% to 96%]; specificity 88% [72% to 97%]) (133).
aphenous vein and internal mammary artery bypass graft
MR can also be combined with rest and adenosine stress
raft flow assessment using phase velocity CMR techniques
133) and suggest superior results.
.2.6. Potential Advantages of CMR Relative to
ther Imaging Modalities
n addition to coronary artery anomalies, CMR is highly
dvantageous for identifying aneurysms or fistula without
he use of contrast materials or exposing patients to ionizing
adiation. These particular advantages are well suited for
ssessing both children and relatively young women that
xperience an increased risk of adverse events associated
ith exposure to ionizing radiation. At expert centers, early
ata suggest CMR may have a role in identifying coronary
rterial stenoses in arterial bypass grafts, as well as excluding
he presence of left main or 3-vessel coronary arterial
isease.
.2.7. Summary of Existing Guidelines and
ppropriate Use Criteria
he ACC/AHA 2002 Guideline Update for the Manage-
ent of Patients With Chronic Stable Angina indicates that
oronary CMR is a suitable method to identify anomalous
rigins of coronary arteries. It may be particularly useful in
ounger individuals with signs or symptoms of myocardial
schemia for the purpose of identifying coronary artery
nomalies and in individuals with the presence of a contin-
ous murmur for identifying an anomalous origin of the left
nterior descending or circumflex artery from the pulmonary
rtery or coronary arterial venous fistulas (134).
Similarly, the ACCF/ACR/SCCT/SCMR/ASNC/
ASCI/SCAI/SIR 2006 Appropriateness Criteria for Car-
iac Computed Tomography and Cardiac Magnetic Reso-
ance Imaging indicates that it is appropriate to use CMR
o evaluate patients suspected of exhibiting coronary anom-
lies (97).
.3. Ischemic Heart Disease
he combination of CMR stress perfusion, function, and
GE allows the use of CMR as a primary form of testing
or: 1) identifying patients with ischemic heart disease
hen there are resting ECG abnormalities or an inability so exercise; 2) defining patients with large vessel CAD
nd its distribution who are candidates for interventional
rocedures; or 3) determining patients who are appropri-
te candidates for interventional procedures. Assessment
f LV wall motion after low-dose dobutamine in patients
ith resting akinetic LV wall segments is useful for
dentifying patients that will develop improvement in LV
ystolic function after coronary arterial revascularization.
he writing committee recognizes the potential advan-
ages of spectroscopic techniques for identifying early
vidence of myocardial ischemia that may or may not be
vident using existing non-CMR methods.
CMR is well suited to detect many of the physiologic
onsequences of ischemia through the assessment of myo-
ardial abnormalities of perfusion, diastolic and systolic
erformance, and metabolism.
.3.1. Myocardial Perfusion Imaging
MR perfusion imaging is performed using a T1-weighted
equence to visualize first passage of a Gd-based contrast
gent in transit through the heart. Following peripheral
njection, the contrast is detected against the background of
ulled (dark) myocardium with rapid enhancement during
asodilation stress. Signal intensity correlates with contrast
oncentration and analysis can be performed in a quantita-
ive, semiquantitative, or qualitative fashion. Qualitatively,
n experienced observer examines the myocardium for
egions of low signal or hypoperfusion relative to normally
erfused segments (Figure 5). Because the contrast agents
apidly redistribute into the extracellular space, quantitative
nalysis is limited to the initial upslope in the tissue
ntensity curve, which has been shown to correlate well with
easures of microsphere blood flow (135).
Validation of CMR perfusion in humans has been per-
ormed in a number of clinical studies employing a variety of
ontrast agents, analysis techniques, and reference standards
136) (Table 5). One study examined signal-intensity time
urves in both patients and controls following dipyridamole
nfusion and bolus injection of a Gd chelate (55). Using a
inear fit to determine the upslope, a threshold value was
efined to distinguish between normal and ischemic myo-
ardium. Diagnostic accuracy was 87% with a high level of
nterobserver agreement. CMR perfusion, 13N-ammonia
ositron emission tomography, and quantitative coronary
ngiography were compared in a study using calculation of
egional signal intensity upslopes (67). Analysis of the
ubendocardial upslope data showed a sensitivity and spec-
ficity of 91% and 94%, respectively, when compared to
3N-ammonia positron emission tomography and greater
han 85% when compared to quantitative angiography. A
tudy combining qualitative analysis of CMR perfusion
mages with LGE identification of myocardial infarction
ielded a sensitivity of 89%, specificity of 87%, and overall
ccuracy of 88% compared to X-ray angiography (142). A
eta-analysis of all CMR perfusion studies demonstrated aensitivity of 91% and specificity of 81% for the diagnosis of
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Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62AD on a per-patient level (146). A multicenter study
omparing CMR perfusion to SPECT suggests a higher
pecificity of CMR perfusion but similar overall accuracy
65). Clinically, it is important to note that to accomplish
esults associated with these multicenter results, appropriate
hysician and staff training is required, and a facility capable
f performing the stress testing is required.
.3.2. Stress Imaging of Ventricular Function
obutamine is commonly administered to evaluate
tress-function CMR with a qualitative evaluation of wall
otion as the dose of dobutamine is increased, an
pplication similar to DS echocardiography. CMR safety
nd efficacy have been assessed extensively. CMR exhibits
igure 5. Myocardial Perfusion Imaging
irst-pass contrast-enhanced perfusion images from a 73-year-old diabetic man usin
ion of 0.075 mM/kg of gadolinium chelate at 4 cc/s. The top panel of short-axis im
he bottom panel obtained in the same short-axis slices 10 minutes later at rest. Th
ty seen at both stress and rest, consistent with myocardial infarction. The mid left v
nferior walls. The apical left ventricle shows an inferolateral perfusion defect at stre
able 5. Sensitivity and Specificity of Recent CMR Perfusion S
oronary Arterial Luminal Narrowings >50%
Investigators (Reference) n Stre
ury et al. (137) 46 Dipyridamole
oyle et al. (138) 184 Dipyridamole
iang et al. (139) 44 Adenosine
shida et al. (140) 104 Dipyridamole/isom
awase et al. (141) 50 Nicorandil
lem et al. (142) 92 Adenosine
agel et al. (55) 84 Adenosine
ilz et al. (143) 171 Adenosine
lein et al. (144) 68 Adenosine
lein et al. (144) 82 Adenosine
akuma et al. (66) 40 Dipyridamole
chwitter et al. (67) 47 Dipyridamole
akase et al. (145) 102 DipyridamoleMR indicates cardiovascular magnetic resonance.
Modified from Nandalur et al. (146).ajor complications (i.e., the development of sustained
entricular tachycardia) in less than 0.1% of subjects,
ndings that are similar to those observed with DS
chocardiography (147).
Studies have shown breath-hold GRE DS CMR to have
high accuracy for detecting ischemia, related in part to
xcellent LV endocardial visualization throughout dobut-
mine/atropine stress protocols (148). DS CMR appears to
e particularly valuable for patients who are poor candidates
or DS echocardiography (149). A list of DS cine CMR
tudies is shown in Table 6. A meta-analysis of stress-
unctional CMR studies demonstrated a sensitivity of 83%
nd specificity of 86% for the demonstration of CAD on a
er-patient level (146).
rid gradient echo–echo planar pulse sequence with parallel imaging during infu-
was obtained during adenosine stress, a 4-minute infusion at 0.14 mg/kg, and
of the left ventricle on the left demonstrates an inferior wall perfusion abnormal-
le demonstrates a large perfusion defect only at stress in the anterolateral and
is normal at rest. cc indicates cubic centimeter; and mM, millimolar.
s on a Per-Patient Basis for Detecting
ent Sensitivity (%) Specificity (%)
97 75
57 78
93 75
handgrip exercise 90 85
94 94
89 87
88 90
96 83
96 83
88 74
81 68
86 70
93 85g a hyb
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic ResonanceCMR tagging may further improve the accuracy of DS
MR for detecting ischemia (161). In addition, in
atients with resting LV wall motion abnormalities,
ow-dose dobutamine CMR is useful for identifying
ontractile reserve indicative of potential for recovering
ystolic thickening after coronary arterial revasculariza-
ion (162). In summary, DS CMR is useful for identify-
ng inducible myocardial ischemia and identifying con-
ractile reserve of LV wall motion after coronary artery
evascularization.
.3.3. Stress Perfusion and Functional Imaging for
rognosis Assessment
rognostic data are now available using both vasodilator and
S CMR methods (52). Three-year event-free survival has
een reported at 99.2% for patients with normal stress
erfusion CMR or DS CMR and 83.5% for those with
bnormal stress perfusion or DS CMR. Ischemia suggested
y stress perfusion CMR or DS CMR is predictive of
ardiac events over the 3-year period with hazard ratios of
2.5 and 5.4, respectively, compared with those without
vidence of myocardial ischemia. In summary, abnormalities
bserved during stress CMR serve as independent predic-
ors of adverse cardiac events.
.3.4. Magnetic Resonance Spectroscopy
pectroscopy provides the CMR basis for the assessment
f myocardial metabolism without the need for contrast
gents or radionuclides (93,163,164). Hydrogen spec-
roscopy may be useful for assessing myocardial cellular
riglyceride levels. Phosphorus spectroscopy has been
sed to measure myocardial energetics. In an early clinical
pplication of Neubauer and his colleagues, 39 patients
ith dilated cardiomyopathy underwent 31P myocardial
able 6. Sensitivity and Specificity of Recent CMR Wall Imagin
oronary Arterial Luminal Narrowings >50%
Investigators (Reference) n St
aer et al. (150) 23 Dipyridam
aer et al. (151)* 32 Dobutam
undley et al. (149) 41 Dobutam
ahnke et al. (152) 40 Dobutam
agel et al. (148) 172 Dobutam
aetsch et al. (153) 79 Adenosin
aetsch et al. (153) 79 Dobutam
aetsch et al. (154) 150 Dobutam
ennell et al. (155) 40 Dipyridam
ennell et al. (156) 25 Dobutam
erkpattanapipat et al. (157) 27 Exercise
challa et al. (158) 22 Dobutam
an Rugge et al. (159) 45 Dobutam
an Rugge et al. (160) 39 Dobutam
MR indicates cardiovascular magnetic resonance; and NA, not available.
*Utilized 2 perfusion territories (left anterior descending coronary artery and combined left cipectroscopy and were followed up at approximately 30 months (93). Kaplan-Meier analysis showed significantly
educed total and cardiovascular mortality for patients
ith greater than 1.6 versus patients with low or less than
.6 PCr/ATP; a Cox model for multivariate analysis
howed that the PCr-to-ATP ratio offered significant
ndependent prognostic information on cardiovascular
ortality. In patients with left anterior descending CAD,
eiss et al. (164) used spatially localized 31P magnetic-
esonance spectra from the anterior myocardium before,
uring, and after isometric hand-grip stress. In patients
ith significant LAD or left main CAD (n16), the
atio decreased from 1.45  0.31 at rest to 0.91  0.24
uring stress (p0.001) and recovered to 1.27  0.38
minutes after exercise.
In a more recent study, handgrip stress was used in
ssociation with 31P spectroscopy in women with cardiac
ymptoms, but without significant angiographic CAD. Of
5 women studied, 20% demonstrated an abnormal reduc-
ion in PCr/ATP with stress (163). In a follow-up study,
he women with an abnormal PCr/ATP had a significantly
reater incidence of recurrent symptoms and rehospitaliza-
ions compared with patients with a normal PCr/ATP
esponse to exercise (165).
.3.5. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR provides high spatial and temporal resolution images
f myocardial perfusion, myocardial function, and identifi-
ation of infarcts using LGE techniques. This unique
ombination offers the ability to reliably identify subendo-
ardial ischemic processes. There is future promise of
otentially incorporating spectroscopic techniques that
ay provide informative information regarding myocardial
udies on a Per-Patient Basis in Detecting
gent Sensitivity (%) Specificity (%)
78 NA
84 NA
d atropine 83 83
89 75
86 86
91 62
d atropine 89 81
78 88
62 100
91 100
79 85
81 83
81 100
91 0.83
x artery/right coronary artery. Modified from Nandalur et al. (146).g St
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ppropriate Use Criteria
he ACC/AHA 2002 Guideline Update for the Manage-
ent of Patients With Chronic Stable Angina indicates that
MR may be used to assess LV performance including
jection fraction (134). In the ACC/AHA Guidelines for
he Management of Patients With ST-Elevation Myocar-
ial Infarction, CMR is recommended for differentiating
T-segment elevation myocardial infarction from aortic
issection in patients for whom this distinction is initially
nclear (Class I, Level of Evidence: B) (166). Within the
CC/AHA/ESC 2006 Guidelines for Management of
atients With Ventricular Arrhythmias and the Prevention
f Sudden Cardiac Death, CMR is probably indicated in
atients with ventricular arrhythmias when echocardiogra-
hy does not provide accurate assessment of LV and RV
unction and/or evaluation of structural changes (Class IIa,
evel of Evidence: B) (167).
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging indicates that the use of CMR stress testing
vasodilator or dobutamine) is appropriate in individuals
ith intermediate pretest probability of CAD or those with
n uninterpretable ECG or those who are unable to exer-
ise. CMR is also appropriate to determine viability prior to
evascularization and establish the likelihood of recovery of
ystolic function with mechanical revascularization. CMR is
ppropriate to assess myocardial viability when determina-
ions from other forms of noninvasive testing are equivocal
r exhibit indeterminate results. The use of CMR stress
esting is appropriate for identifying cardiac risk in patients
ith prior coronary angiography or stenoses of unclear
ignificance (97).
At present, ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging is uncertain of the utility of CMR stress testing
rocedures in individuals with: 1) an interpretable ECG and
etter ability to exercise; 2) a high pretest probability of
oronary disease; 3) acute chest pain with an intermediate
igure 6. Infarct Imaging
mages from the same patient as in Figure 5. The panel of images demonstrates ph
btained 10 minutes after 0.15 mM/kg of gadolinium was infused intravenously. Th
eft ventricle show a 25% to 50% transmural inferior infarction. Putting this data toge
schemia in the mid and apical inferior walls as well as mid anterolateral ischemia, cretest probability of coronary disease; 4) no ECG changes, iith serial cardiac enzymes remaining negative; 5) a prior
quivocal stress test from another modality; 6) intermediate
AD risk profile using Framingham criteria; 7) intermedi-
te preperioperative cardiovascular risk; or 8) post percuta-
eous intervention myocardial necrosis (97).
.4. Myocardial Infarction/Scar
GE-CMR can be used for identifying the extent and
ocation of myocardial necrosis in individuals suspected
f having or possessing chronic or acute ischemic heart
isease.
.4.1. Infarct Imaging
he spatial extent of LGE closely mirrors the distribution
f myocyte necrosis in the early period following infarction
nd that of collagenous scar seen at 8 weeks (168), whereas
n regions of the heart subjected to reversible injury, the
etention of contrast does not occur (76). LGE accurately
elineates infarction as defined by histology at various time
oints following injury (169) (Figure 6). When compared
ith SPECT, LGE is more reliable in detecting subendo-
ardial infarct scar (68,170). LGE also improves the detec-
ion of RV infarction (171).
Transmural extent of infarct scar, as determined on LGE,
s inversely related to the functional recovery of LV wall
otion following acute infarction. Previous studies have
oted an inverse relationship between transmural extent of
GE and segmental recovery of function (172). The best
redictor of improved wall thickening and global function
as the extent of dysfunctional myocardium that had either
o LGE or less than 25% transmurality of LGE.
Investigators have exploited the enhanced sensitivity of
GE to study small infarctions after percutaneous interven-
ion (173,174), demonstrating enzyme leak and discrete
reas of LGE in the target vessel territory. LGE persists at
ollow-up scans 3 to 12 months after initial procedures.
imilar studies have been performed in patients undergoing
oronary artery bypass surgery (175).
Evidence suggests that the presence of any LGE may be
valuable tool for predicting major adverse cardiac events
nd cardiac mortality. In a study of patients evaluated for
nsitive inversion recovery gradient echo images in the same 3 short-axis locations
l left ventricle shows a 50% transmural inferior infarction while the mid and apical
ith Figure 5, the findings are consistent with an inferior infarction with peri-infarct
tent with multivessel coronary artery disease. mM indicates millimolar.ase-se
e basaschemic heart disease for various reasons, the presence of
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic Resonanceny LGE was found to be the strongest predictor of major
r adverse cardiac events, independent of LV ejection
raction and other conventional clinical markers (78). A
tudy of randomly chosen patients greater than 70 years old
howed that more than 24% had evidence of LGE, over
hree fourths of which were unrecognized myocardial in-
arction (176). Thus, the finding of LGE is likely to become
n important marker of silent infarction and prognosis.
Border zones of infarcts may have prognostic utility in
atients sustaining prior infarction. These regions experi-
nce LGE at a level above the intensity of normal back-
round intensity, but below the 2 standard deviations in
ntensity above background normal tissue that is used to
dentify infarcts. This “intermediate” intensity is due in part
o a mixture of healthy and diseased myocytes and, in small
tudies, had been found associated with future incidences of
entricular arrhythmias (34,177). Investigators have also
stablished the clinical importance of microvascular obstruc-
ion (MO) regions, sometimes referred to as no-reflow
ones (178). Acutely, tissue edema, hemorrhage, and in-
ammation can increase infarct volume by as much as 25%
179). Beyond these necrotic regions, dysfunctional, non-
ecrotic tissue coexists, which has the potential for func-
ional recovery (180). Thus, a region of systolic dysfunction
ollowing myocardial infarction will generally consist of a
ombination of reversibly injured (stunned) and irreversibly
njured (infarcted) myocardium, with the severity of dys-
unction a poor marker for the transmural extent of necrosis
181). With the development of LGE, these tissue states
an be distinguished within the same segment of myocar-
ium (Figure 7). Studies have demonstrated that regions
ith MO are nonviable with no recovery of function at 7 to
weeks post-myocardial infarction in these territories
182,183). MO, defined as hypoenhancement at 1 to 2
inutes after Gd injection, is also a prognostic marker of
ostinfarction complications even after controlling for ab-
olute infarct size (62). Furthermore, MO is a better
redictor of major adverse cardiac events than LGE-defined
nfarct size (62).
.4.2. LV Remodeling After Acute Myocardial Infarction
he technique of LGE has enabled investigators to simul-
aneously chronicle changes in infarct scar and LV function
nd geometry following acute myocardial infarction. LGE
nfarct size and transmurality appear to slightly decline over
he first 1 to 2 months from acute myocardial infarction,
ith involution of LGE contours (184), observed to a
reater degree among patients with MO. Apoptosis and
ellular loss likely play a role in this infarct involution (178).
.4.3. Potential Advantages of CMR Relative to
ther Imaging Modalities
ue to high spatial resolution and few limitations imposed
y body habitus, CMR provides a noninvasive mechanism
o reliably identify subendocardial or transmural infarctions. tegions of microvascular obstruction can be identified
ithin infarcts. This imaging may be combined with other
tructural or functional heart assessments to provide a
omprehensive cardiac assessment of patients sustaining
yocardial injury.
.4.4. Summary of Existing Guidelines and
ppropriate Use Criteria
he ACC/AHA 2005 Guideline Update for the Diagnosis
nd Management of Chronic Heart Failure in the Adult
ndicates the use of LGE to identify myocardial viability in
car tissue (96).
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging indicates the appropriate use of LGE for deter-
ining the location and extent of myocardial necrosis
ncluding no-reflow regions, assessments of patients post
cute myocardial infarction, assessing viability prior to
evascularization, establishing the likelihood of recovery of
unction with coronary artery revascularization, and to
etermine viability prior to revascularization, and assessing
iability when low-dose dobutamine echocardiography has
rovided indeterminate results (97).
.5. Nonischemic Cardiomyopathy/Myocarditis
MR may be used for assessment of patients with LV
ysfunction or hypertrophy, or suspected forms of car-
iac injury not related to ischemic heart disease. When
igure 7. Microvascular Obstruction of a Patient After
nteroseptal Myocardial Infarction
his figure is a short-axis late gadolinium-enhanced inversion recovery gradient
cho axis image obtained 10 minutes after gadolinium infusion in a patient on Day
after reperfused anteroseptal myocardial infarction. Note the transmural late gad-
linium enhancement in the anteroseptum. The arrow points to a region of micro-
ascular obstruction in the core of the infarction that represents a region of
apillary damage to the extent that contrast is unable to fill this region even 10
inutes after contrast. MO is generally only seen in the first 7 to 10 days post-
yocardial infarction and signifies an infarction and patient with poorer prognosis
han those without MO. MO indicates microvascular obstruction.he diagnosis is unclear, CMR may be considered to
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Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62dentify the etiology of cardiac dysfunction in patients
resenting with heart failure including: 1) evaluation of
ilated cardiomyopathy in the setting of normal coronary
rteries; 2) patients with positive cardiac enzymes with-
ut obstructive atherosclerosis on angiography; 3) pa-
ients suspected of amyloidosis or other infiltrative dis-
ases; 4) HCM; 5) arrhythmogenic RV dysplasia; or 6)
yncope or ventricular arrhythmia.
Nonischemic cardiomyopathies include genetic forms
HCM, arrhythmogenic right ventricular cardiomyopathy
ARVC], LV noncompaction, and others), mixed forms
dilated cardiomyopathies [DCM], and restrictive cardio-
yopathies), and acquired forms (myocarditis, stress-
nduced cardiomyopathy, peripartum cardiomyopathy, and
thers). Knowledge of the etiology of a cardiomyopathy is
mportant for diagnosis, therapy, and prognosis. CMR
rovides a noninvasive measure to provide this knowledge
hrough determination of cardiac chamber size and struc-
ure, LV and RV regional and global function, perfusion,
etabolism, and tissue composition.
.5.1. Hypertrophic Cardiomyopathy
nappropriate myocardial hypertrophy, loss of diastolic func-
ion, development of intramyocardial fibrosis, and possible
ynamic systolic obstruction of the LV outflow tract are
allmarks of HCM. CMR accurately quantifies myocardial
ass and regional wall thickness in all myocardial segments. In
bstructive HCM, systolic anterior movement of the anterior
itral valve apparatus and a turbulent jet can be identified on
ong-axis cine bright blood imaging studies. The area of the
bstructed LV outflow tract can be quantified for diagnosis and
irecting therapy longitudinally over time (185). Specific pat-
erns of focal or regional LGE have been reported in HCM
186) and found to be associated with regional hypertrophy,
ecreased systolic thickening, and perfusion deficits (187).
hese patterns can be scattered throughout the hypertrophied
yocardium and are dissimilar to the endocardial based pat-
erns of LGE seen after myocardial infarction. Preliminary
ata suggest a prognostic relevance of LGE in patients with
CM (89,186). CMR is also very sensitive for detecting
CM in the first-degree relatives of those with clinical HCM
188). During treatment, CMR can readily identify the effects
f alcohol septal ablation (25). LGE in hypertrophied muscle
as been shown to be associated with increased fibrosis within
he LV myocardium.
.5.2. Arrhythmogenic Right Ventricular
ardiomyopathy
haracteristics of ARVC include global or regional dilatation
nd dysfunction of the RV (and in some cases, the LV)
yocardium. Furthermore, fatty and/or fibrous replacement
ay be found. Morphological and functional targets for CMR
nclude regional or global wall motion abnormalities, aneu-
ysms, and segmental or global dilation, as well as global
ypokinesis, with quantitative analysis of RV volume and
unction (189,190). The role of CMR in ARVC has been Decently reviewed (191). In contrast to earlier reports, the
dentification of myocardial fat is not the only structural wall
bnormality associated with ARVC (192) and may be less
pecific for the disease (192). LGE of RV fibrosis has been
eported as a useful marker (Figure 8) (193). Combined
rotocols involving determination of wall motion and RV
issue characteristics may provide an excellent diagnostic accu-
acy, as shown in patients with genetically defined disease
194). Recent studies in gene carriers have also emphasized the
mportant role of LV involvement in ARVC (195).
.5.3. Noncompaction Cardiomyopathy
oncompaction cardiomyopathy is described as a cardiomy-
pathy that occurs due to an autosomally dominant inherited
rait in which the middle and apical segments exhibit a thin
ompact wall with regional dilatation, dysfunction, and signif-
cant hypertrabeculation (Figure 9). An end-diastolic ratio of
oncompacted to compacted LV myocardium of greater than
r equal to 2.3 defines the condition (196). Also, LV wall
otion abnormalities, global dysfunction, or coronary intra-
entricular thrombi are often present in the disorder. Refined
iagnostic criteria may be forthcoming as this disorder be-
omes recognized with greater frequency.
.5.4. Dilated Cardiomyopathy
iagnostic targets for CMR in DCM include progressive
V dilation, LV systolic dysfunction, and regional midwall
yocardial fibrosis (88). Recently, focal septal fibrosis in
igure 8. Late Gadolinium Enhancement in ARVC in a
atient With Family History of ARVC
pper panel: irregular silhouette of the free RV wall with microaneurysm. Lower
anel: evidence for LGE of the RV wall (arrowheads), but also focal fibrosis of the
nterventricular septum (arrow). ARVC indicates arrhythmogenic right ventricular car-
iomyopathy; LGE, late gadolinium enhancement; and RV, right ventricular.CM, the so-called “midwall sign,” has been linked to
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic Resonanceentricular arrhythmia (197). The presence of fibrosis iden-
ified with LGE has been found to be associated with
dverse cardiac events (85).
.5.5. Acute Viral Myocarditis
uantification of global myocardial signal intensity
hanges on T2-weighted CMR reflecting inflammation
nd especially edema offers a high diagnostic accuracy to
etect acute myocarditis (198). Reflecting irreversible
njury, a typical pattern of regional, typically subepicar-
ial fibrosis, can be visualized (90) (Figure 10). With
ombined analysis of T1- and T2-weighted scans,
eightened diagnostic accuracy for identifying active
yocarditis is achieved (198,199). CMR is considered
ne of the most important diagnostic tools in the workup
f patients with myocarditis (91,200). An expert consen-
us document on the application, evaluation, and report-
ng of CMR in myocarditis has been developed (201).
.5.6. Sarcoidosis
p to 50% of patients with pulmonary sarcoidosis have
ardiac involvement, although only 5% have cardiac symp-
oms. Myocardial involvement, however, is the leading
igure 9. Late Gadolinium Enhancement in Left Ventricular Noncom
pper panels: systolic long-axis (left) and short-axis (right) still frames. Lower panels
ate Gd enhancement study using a short inversion time (fibrosis appears with low S
arrowhead) are shown. Gd indicates gadolinium; LGE, late gadolinium enhancementause of death in these patients. CMR can visualize myo- tardial inflammation using contrast-enhanced techniques.
arly contrast enhancement identifies territories exhibiting
yocardial inflammation, whereas LGE shows areas of
rreversible injury (Figure 11) (202).
.5.7. Amyloidosis
yocardial amyloid infiltration is frequent among pa-
ients with systemic amyloidosis and leads to apparent
yocardial hypertrophy with impaired ventricular func-
ion. Because of abnormally short T1 and T2 relaxation
imes and a significant accumulation of Gd within
ffected tissue (79), the diagnosis of cardiac amyloidosis
an be established with a high accuracy. It is important to
ote that in amyloidosis, Gd is cleared much faster from
he blood than in other patients. Blood will therefore
ppear with a low signal in contrast-enhanced T1-
eighted images (Figure 12).
.5.8. Hemochromatosis
ardiac iron overload in diseases such as thalassemia may
ead to dilatation, hypertrophy, and dysfunction. The intro-
uction of myocardial T2* quantification offers a reliable
arameter for monitoring patients undergoing chelation
tion
short-axis late Gd enhancement image showing several areas of fibrosis. Right:
firmation of lesions in the myocardium (arrows) and in the trabecular tissue
SI, signal intensities.pac
: left:
I). Conherapy (203). T2* correlates well with LV systolic function,
b
p
q
t
a
(
3
O
C
L
r
F
I
a
a ium w
F
L
w
2634 Hundley et al. JACC Vol. 55, No. 23, 2010
Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62ut not with liver iron content or serum ferritin. Since
rognosis is mainly determined by cardiac involvement, T2*
uantification within the LV myocardium has been shown
o be a more efficacious marker of cardiac iron involvement
nd guidance of chelation therapy than serial liver biopsies
203,204).
igure 10. Cardiovascular Magnetic Resonance Tissue Characteri
mages obtained by different sequences in the same 2-chamber view are shown. Pan
bnormality. Panel C shows increased signal intensity in a T2-weighted image, indica
pical blood due to slow blood flow (thin arrow). Panel D visualizes a delayed gadolin
igure 11. Late Gadolinium Enhancement in Arrhythmogenic Righteft panel: long-axis view of a late gadolinium enhancement study showing a transmural le
ith the same lesion (arrow)..5.9. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR can be used to provide excellent serial assessment of
V and RV function and volumes. In addition, it can
eliably visualize the cardiac apex (95). This is important in
in a Patient With Acute Myocarditis
(diastolic) and B (systolic) indicate a basal-anterior and apical-inferior wall motion
dema as a feature of acute injury (arrowheads). Note the increased signal of the
ashout indicating irreversible injury (arrowheads).
tricular Cardiomyopathy in a Patient With Cardiac Sarcoidosiszation
els A
ting eVension in the basal lateral wall (arrow). Right panel: cross-referenced short-axis view
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic Resonancelanning therapeutic interventions. Importantly, the unique
bility of CMR to characterize disease-specific tissue abnor-
alities and assess cardiac function affords physicians an
bility to diagnose the etiology and monitor therapy in
atients with cardiomyopathy.
.5.10. Summary of Existing Guidelines and
ppropriate Use Criteria
he ACC/AHA 2005 Guideline Update for the Diagnosis
nd Management of Chronic Heart Failure in the Adult
ndicates the utility of CMR to confirm the presence of iron
verload (96).
The writing committee recognizes the ACCF/ACR/
CCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 Appro-
riateness Criteria for Cardiac Computed Tomography and
ardiac Magnetic Resonance Imaging for utilizing CMR to
valuate dilated cardiomyopathy in the setting of normal
oronary arteries, or evaluating cardiomyopathies in indi-
iduals with positive cardiac enzymes without obstructive
therosclerosis on angiography. In addition, CMR is appro-
riate to evaluate specific cardiomyopathies including infil-
rative (amyloid, sarcoid), HCM, LV dilated cardiomyop-
thy (including cardiotoxic therapy), patients suspected of
RVC, or individuals suspected of cardiomyopathy pre-
enting with syncope or ventricular arrhythmia (97).
.6. Assessment of Valvular Heart Disease
MR may be used for assessing individuals with valvular
eart disease in which evaluation of valvular stenosis,
egurgitation, para- or perivalvular masses, perivalvular
omplications of infectious processes, or prosthetic valve
isease are needed. CMR is particularly useful in iden-
ifying serial changes in LV volumes or mass in patients
ith valvular dysfunction.
In patients with valvular heart disease, CMR is uniquely
uited to identify and assess the magnitude of valvular
igure 12. Late Gadolinium Enhancement in Arrhythmogenic Right
eft panel: long-axis view of a late Gd enhancement study (10 min post Gd administ
rom blood pool (low signal intensity of the ventricular lumen). Right panel: confirmat
d indicates gadolinium.tenosis or regurgitation, as well as determine the influence of the valve lesion on LV performance. The subjective
resence or absence of valvular disease can be made on cine
RE sequences by visualization of a signal void/turbulent
et above or below the valve in systole or diastole. Although
SFP imaging is the preferred cine CMR method for most
unctional imaging, standard GRE imaging may be prefer-
ble for jet visualization because of its longer echo time
205,206). Sequences such as these with relatively high
emporal resolution (20 to 40 ms) can be used to measure
he area of valve leaflet opening in systole for either aortic
alve stenosis (207), or in diastole for mitral valve stenosis.
lthough CMR planimetry of the aortic valve has been
hown to be relatively accurate, CMR is likely to underes-
imate mitral stenosis (i.e., overestimate the valve area)
208,209) because of the translational motion of the heart.
ewer sequences, currently in development, that incorpo-
ate mitral annular tracking devices, may help resolve this
ssue.
A quantitative assessment of single-valve regurgitant
isease can be obtained by calculating the difference be-
ween RV and LV stroke volumes (210). A more elegant
uantitative assessment of valvular stenosis and regurgita-
ion may also be performed using velocity-encoded PC
equences (210,211). These sequences display both a mag-
itude and a phase image. The phase image can be used to
btain the peak and mean velocity of a stenotic jet as well as
ow through a prescribed area. Velocities can then be
pplied in the modified Bernoulli equation to calculate the
ressure gradient (47,212,213) across a stenotic valve
47,212). Forward and reverse volume across a valve can also
e assessed to determine the regurgitant volume and regur-
itant fraction to quantify the extent of valvular insufficiency
3,214–216). In-plane PC-CMR can be used to assess
irection of highly eccentric jets such as occur in mitral
egurgitation. Importantly, CMR defines the consequence
tricular Cardiomyopathy in a Patient With Cardiac Amyloidosis
showing extensive, diffuse myocardial Gd uptake (arrows) with early clearance
ort-axis view showing the mainly subendocardial distribution of the Gd (arrow).Ven
ration)f the valvular lesion on LV performance (LV regional
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Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62unction, dimensions, volumes, mass, and ejection fraction):
ll parameters used to direct medical therapy or determine
he optimal time for surgical intervention (3,217).
CMR may also be useful in assessing valvular masses.
hese masses can include either true primary valvular
umors such as papillary fibroelastomas, or valvular vegeta-
ions or thrombi such as in bacterial endocarditis (218–220).
equences used to assess the valve for masses would include
ine SSFP in the plane of the valve to assess for mass
obility (218). As valvular vegetations may be quite small,
D SSFP imaging with a T2 preparatory pulse and fat
uppression may be useful in the plane of the valve (221). In
ases where the tumor or vegetation is causing valvular
nsufficiency, quantitative evaluation should be performed.
.6.1. Potential Advantages of CMR Relative to
ther Imaging Modalities
rinciples (modified Bernoulli equation, continuity equa-
ion, planimetry) used in other modalities to determine
alvular stenosis are similar in CMR, with the latter using
C sequences to obtain transvalvular velocity measures
211). In individuals with valvular regurgitation, CMR is
nique in that it is used to directly quantify valvular
egurgitation in mL/min rather than provide an estimate
sing another surrogate measure. Although several small
tudies identify potential utility of CMR in assessing pa-
ients with valvular heart disease, studies with larger patient
umbers and comparisons with echocardiography would be
seful to extend applicability. In addition, CMR can be used
or serial assessments that accurately quantify LV and RV
olume and function, important information in patients
ith chronic valvular heart disease that is often used to
etermine the optimal time for surgical or percutaneous
nterventions.
.6.2. Summary of Existing Guidelines and
ppropriate Use Criteria
he ACC/AHA 2006 Guidelines for the Management of
atients With Valvular Heart Disease recommends CMR
or initial and serial assessment of LV volume and function
t rest in patients with aortic regurgitation and suboptimal
chocardiograms (Class I, Level of Evidence: B) (222). In
ddition, CMR is recommended in patients with bicuspid
ortic valves when morphology of the aortic root or ascend-
ng aorta cannot be assessed accurately by echocardiography
Class I, Level of Evidence: C) and is probably recommended
n patients with bicuspid aortic valves when aortic root
ilation is detected by echocardiography to further quantify
everity of dilation and involvement of the ascending aorta
Class IIa, Level of Evidence: B) (222).
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging indicates the use of CMR to characterize native
nd prosthetic cardiac valves including planimetry of ste-
otic valves and quantification of regurgitant disease. CMR may be especially useful in individuals with technically limited
mages from echocardiography or in those patients who are not
andidates for transesophageal echocardiography. CMR is also
seful for assessing serial changes in LV or RV mass or
olumes and quantification of valvular heart disease (97).
.7. Cardiac Masses
MR may be used for clinical evaluation of cardiac
asses, extracardiac structures, and involvement and
haracterization of masses in the differentiation of tu-
ors from thrombi.
CMR can be a valuable adjunct for the evaluation of
atients with suspected pericardial or cardiac masses. Car-
iac masses can be categorized as intracavitary thrombus,
rimary tumors (arising from cardiac tissue), and secondary
ardiac tumors (metastasis from noncardiac tissue) (223,224).
standard CMR approach for evaluation of structure and
unction would routinely involve dark blood images in the
xial, sagittal, and coronal planes of the entire chest fol-
owed by bright blood (e.g., SSFP) cine imaging of the heart
rom base to apex in both short- and long-axis views.
ommon structures that may mimic or raise concern for
rue cardiac tumors, often due to incomplete coverage or
isualization, include prominent eustachian valves, Chiari
etwork, crista terminalis, lipomatous interatrial septum,
ericardial cysts, and large hiatal hernias. Often many of
hese pseudocardiac tumors are incompletely categorized on
ther noninvasive cardiac imaging studies. In patients with
ardiac masses, CMR can be used to characterize tissue
ithin the mass (225).
.7.1. Characterization of Cardiac Masses
or intracavitary cardiac masses, the ability to distinguish a
ardiac tumor from thrombus is important. Cardiac thrombi
ccur in the left atrial appendage in association with atrial
brillation, and LV thrombi often occur with dilated is-
hemic cardiomyopathy. Intracavitary mural thrombi may
e difficult to identify using other imaging techniques.
MR has been shown to be very sensitive for the detection
f LV thrombi (226–228). This is in part due to the utility
f CMR tissue characterization with LGE. LGE, which is
ypically used for detection of myocardial fibrosis or scar,
an be used with long inversion recovery times for improved
ifferentiation of enhancing cardiac masses from nonen-
ancing bland thrombus (229). CMR may have utility for
dentifying cardiac cavitary thrombi in patients sustaining
ardioembolic stroke.
.7.2. Benign Versus Malignant Cardiac Masses
nce a cardiac mass is identified, the presence of hetero-
eneous infiltration of the myocardium, vascular invasion, or
ther signs of metastasis (e.g., metastatic pleural effusion
nd/or mediastinal adenopathy) can be used to differentiate
enign versus malignant tumors (230,231). Primary cardiac
umors including myxomas, papillary fibroelastomas, fibro-
as, and lipomas are often benign. Many of these tumors
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic Resonanceave characteristic anatomic locations and specific tissue
haracteristics. The most common primary malignant tu-
ors of the heart can be classified as cardiac sarcomas (the
ost common subtype is angiosarcomas), and primary
ardiac lymphomas. These malignant tumors can extend
ocally and involve the pericardium and, with tissue charac-
erization, have indistinct margins and heterogeneous Gd
nhancement. First-pass imaging through a cardiac mass
ay help distinguish vascularized lesions, such as renal
arcinoma metastases, from other nonvascular lesions.
.7.3. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR has been shown to be beneficial for characterizing
f cardiac tumors as benign or malignant (232). In
omparison to other imaging modalities, CMR has the
enefits of multiplanar image acquisition, high spatial
esolution imaging, large field of view, and tissue char-
cterization.
.7.4. Summary of Existing Guidelines and
ppropriate Use Criteria
he writing committee recognizes that no existing guide-
ines are established for the evaluation of cardiac mass with
MR.
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging indicates the use of CMR for evaluation of
ntracardiac and extracardiac masses including suspected
umors or LV thrombi (97).
.8. Pericardial Disease (Constrictive Pericarditis)
MR may be used as a noninvasive imaging modality
o diagnose patients with suspected pericardial disease.
MR can provide a comprehensive structural and
unctional assessment of the pericardium as well as
valuate the physiological consequences of pericardial
onstriction.
In 2 respects, CMR is useful for assessing patients
uspected of constrictive pericardial disease. First, with
MR, the entire pericardium can be visualized without
egard to body habitus or prior surgical procedures (233–237).
n constriction, a pericardial thickness greater than or equal
o 4 mm is abnormal and visually seen. Second, CMR can
e used to evaluate the physiologic impact of abnormal
ericardial thickening. Distension of the hepatic veins and
attening of the interventricular septum are signs of accom-
anying elevated right-sided pressures. Paradoxical motion
f the interventricular septum may be seen as the right-sided
ressures equalize or exceed those on the left during
iastole. Real-time cine CMR can be used to evaluate for
entricular interdependence to help distinguish constrictive
ericarditis from restrictive cardiomyopathy (238,239).
Effusive constriction results from a pericardial effusionhat has become organized or gelatinous (240). The peri- dardial space tends not to be homogeneous on various pulse
equences. Tagged cine can be used to demonstrate failure
f the tags to distort with systole. Pericardial adhesions may
e seen with a normal-thickness pericardium and result in
unctional constriction. They are best appreciated with
agged cine (Figure 13) (241). Rather than the normal
lippage of the pericardium across the myocardium during
ystole, there is tethering of the myocardium, which impairs
iastolic filling.
Right heart catheterization has been used to identify the
emodynamic consequence of right-sided heart failure, but
he initial criteria that examined end-diastolic pressure
elationships have been of limited predictive value (242).
bnormal ventricular interdependence can improve the
igure 13. Cardiovascular Magnetic Resonance Findings
ssociated With Pericardial Disease
anel A: a short-axis, cine-tagged imaging is provided. Along the posterior wall of
he left ventricle (white arrow), tag deformation is absent, indicating pericardial
dhesions. Panel B: dark blood T1-weighted spin echo images are provided, indi-
ating thickened pericardium along the anterior surface of the right ventricle and
orresponding tubular deformity of the ventricles. Advanced lung disease is also
oted.iagnostic accuracy of right heart catheterization (243).
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ther Imaging Modalities
he marked utility of CMR for assessment of pericardial
isorders resides in the fact that comprehensive visual-
zation of the LV endocardium may occur, and the
hysiologic consequences of abnormal pericardial thick-
ning can be obtained without exposure to ionizing
adiation (244).
.8.2. Summary of Existing Guidelines and
ppropriate Use Criteria
he writing committee recognizes that no existing guide-
ines are established for assessment for pericardial disease
ith CMR.
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging indicates CMR is appropriate for evaluation of
ericardial conditions, including pericardial mass and peri-
ardial constriction (97).
.9. Congenital Heart Disease
MR may be used for assessing cardiac structure and
unction, blood flow, and cardiac and extracardiac con-
uits in individuals with simple and complex congenital
eart disease. Specifically, CMR can be used to identify
nd characterize congenital heart disease, to assess the
agnitude or quantify the severity of intracardiac shunts
r extra cardiac conduit blood flow, and to evaluate the
orta and pulmonary arteries to assess the pathological
nd physiologic consequences of congenital heart disease
n left and right atrial and ventricular function and
natomy.
CMR can be used to characterize 3 important aspects
f patients with congenital heart disease both pre- and
ostoperatively: the anatomy of the lesion (including the
tria, ventricle, and great vessels and their respective
onnections), the physiology (including cardiac and con-
uit blood flow), and the assessment of ventricular
unction (in order to determine how the heart is handling
he abnormal anatomy and/or physiology). CMR is
specially attractive in congenital heart disease where
omplex anatomic details need to be ascertained, as well
s in the pediatric age range where ionizing radiation is a
rave concern.
.9.1. Anatomy
MR has been used to delineate anatomic details of
ongenital heart disease for over 2 decades. CMR determi-
ation of anatomy has been validated against other gold
tandard techniques and often CMR-derived information
lters therapy (245,246). 3D SSFP and Gd imaging has
een shown to be particularly useful in giving an overview of
omplex anatomy in congenital heart disease. (.9.2. Physiology
ine and PC velocity mapping CMR provide physicians
ith a noninvasive method to assess the physiologic impor-
ance of consequential heart lesions. For example, the
ulmonary to systemic flow ratio (Qp/Qs) of shunt lesions
e.g., atrial and ventricular septal defects) can be quantified
sing CMR (48,247,248). PC-CMR can also provide
uantification of collateral blood flow in aortic coarctation
249,250), determine caval contributions to each lung in
ontan patients (251), measure cerebral blood flow in
uperior-cavopulmonary connections (252), or quantify re-
urgitant fractions in patients after repair of tetralogy of
allot (253,254). Newer techniques such as ultrafast, time-
esolved 3D contrast-enhanced MRA expand the utility of
MR to assess physiology in congenital heart disease. This
s particularly useful in assessing disorders of the pulmonary
irculation (Figure 14).
.9.3. Biventricular Function
here are multiple studies reinforcing the accuracy of CMR
or biventricular function in congenital heart disease
255,256). The high accuracy and reproducibility of CMR
or ventricular cavity size and systolic function is particularly
seful in the congenital heart disease population because
hese patients undergo numerous procedures that change
he physiology and may affect ventricular performance due
o cardiopulmonary bypass or deep hypothermic circulatory
rrest (257,258).
.9.4. Congenital Aortic Disease
oarctation, Complete Interruption, and
seudo-Coarctation
oarctation of the aorta, representing abnormal placation of
he tunica media of the posterior aortic wall proximal to the
igamentum arteriosum, accounts for approximately 5% of
ll congenital heart disease (259). Most coarctations found
n adults are juxtaductal in location and “simple,” being
ound in the absence of other cardiovascular abnormalities.
n the other hand, “complex” coarctations are often present
n infancy due to their associated intracardiac anomalies.
Anatomic CMR (combined spin echo and cine GRE or
SFP) (114,118,120–122) and/or CE-MRA (121–123)
lone has been shown to be comparable to conventional
ngiography for delineation of the location and degree of
tenosis due to coarctation. A large series of patients with
ngiographically confirmed congenital obstructive aortic
nomalies, including coarctation and interruption, reported
diagnostic sensitivity of 89%, specificity of 84%, and
ccuracy of 86% for CMR (spin echo and cine GRE or
SFP) and 98%, 99%, and 98%, respectively, for CE-MRA
260). However, a general superiority of CMR (spin echo,
ine, dynamic PC) with CE-MRA over other imaging
odalities, including echocardiography, for combined ana-
omic (location and severity of narrowing) and physiologic
trans-coarctation pressure gradient determination, collat-
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic Resonanceral flow measurement) assessment of coarctation has been
emonstrated (114,118,121,126,129,260,261). Accord-
ngly, CMR (262) or CE-MRA (263) can effectively dis-
inguish pseudocoarctation (no hemodynamically significant
arrowing, poststenotic flow, or collateral vessels) from true
oarctation of the aorta. In addition, CMR can be used to
dentify aneurysms of the central nervous system circulation
n patients with coarctation.
CMR and CE-MRA can also be effectively used to assess
ostoperative complications for coarctation, including reste-
osis and pseudoaneurysm formation (114,121,135,264).
irect visualization of collateral vessels by CE-MRA and
ercent increase in flow from proximal to distal descending
horacic aorta are more reliable indicators of hemodynamic
ignificance of restenosis following surgical repair of coarc-
ation than arm–leg blood pressure gradient (136). The
resence of metallic stents following angioplasty can inter-
ere with postintervention assessment of the coarctation site
y CMR/CE-MRA. However, physiologic evaluation of
hanges in collateral circulation before and after interven-
igure 14. Examples of Cardiovascular Magnetic Resonance in Co
he upper left panel is a cine CMR of a patient with double outlet right ventricle dem
he lower left panel is a 3-dimensional reconstruction of a single-ventricle patient af
ior view) and a bilateral bidirectional cavopulmonary connection where the LSVC and
hich is a posterior view). The rightward panels are from a patient with tetralogy of F
f the MPA. This technique encodes flow into and out of the imaging plane with dire
nd the bottom image demonstrates retrograde or regurgitant flow (black). The frame
ascular magnetic resonance; LPA, left pulmonary artery; LSVC, left superior vena ca
SVC, right superior vena cava.ion is still feasible (142). 1rch Anomalies and Vascular Rings
he failure of embryonic vascular arches to fuse and regress
n the usual manner during the formation of the aortic arch,
ulmonary arteries, and ductus arteriosus can cause a wide
pectrum of vascular congenital abnormalities of the aortic
rch and its branches (265). These abnormal vascular
tructures, especially when they constitute a true vascular
ing (i.e., double aortic arch, right aortic arch with aberrant
eft subclavian artery, or mirror-image right aortic arch with
eft-sided ligamentum arteriosum) may cause varying de-
rees of compression of the trachea and/or esophagus, with
esulting symptoms ranging from none to severe stridor,
yspnea, cyanosis, and dysphagia. These arch anomalies/
ascular rings require specific surgical corrective measures
ased on well-delineated anatomic and physiologic assess-
ent of the abnormalities by imaging, such as CMR and/or
E-MRA (148). CE-MRA, complemented by flow-
ensitive techniques to evaluate stenosis, is very useful for
etecting congenital vascular abnormalities (123,129,
ital Heart Disease
ting semilunar valve morphology. The PV is trileaflet, whereas the AoV is bicuspid.
tic to pulmonary anastamosis (arrow on leftward image, which is an anteroposte-
are connected to the LPAs and RPAs (best visualized on the rightward image,
fter repair with pulmonary regurgitation using through-plane phase-contrast imaging
ity encoded as white or black; the top image demonstrates antegrade flow (white),
e acquired at peak systole and diastole. AoV indicates aortic valve; CMR, cardio-
PA, main pulmonary artery; PV, pulmonary valve; RPA, right pulmonary artery; andngen
onstra
ter aor
RSVC
allot a
ctional
s wer
va; M49,164) and diagnosing potentially life-threatening com-
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ings (163).
.9.5. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR is advantageous for the assessment of patients with
ongenital heart disease because it can visualize structures
ithin and external to the heart with minimal impediments
elated to body habitus. In lesions affecting the right heart,
MR provides excellent visualization and comprehensive
olume determinations regardless of RV shape. This is
articularly important in patients with congenital heart
isease in which abnormalities of pulmonary artery anatomy
r blood flow can raise RV afterload. Importantly, CMR
an be used to quantify in 3D anatomy, physiology, and
unction and, in pediatric patients can be used to acquire
nformation relating to congenital heart disease without
onizing radiation (266,267), or the need for iodinated
ontrast (268,269). Because of concerns regarding exposure
f pediatric patients to ionizing radiation (270), the writing
ommittee feels CMR (rather than cardiovascular computed
omography) may be preferred to address questions related
o pediatric congenital heart disease when 1) there is an
ppropriate indication for tomographic imaging and 2)
here is local expertise present to perform and interpret the
MR studies.
.9.6. Summary of Existing Guidelines and
ppropriate Use Criteria
he ACC/AHA 2008 Guidelines for the Management of
dults With Congenital Heart Disease recommends CMR
Class I, Level of Evidence: B) for assessment of patients
ith aortic coarctation and (Class I, Level of Evidence: C) for
ubsequent evaluations of repaired aortic coarctations.
MR is also recommended (Class I, Level of Evidence: C)
or baseline imaging of patients with pulmonary stenosis. In
enters with adequate expertise, CMR is useful (Class I,
evel of Evidence: B) for the initial screening of patients with
uspected congenital coronary anomalies. Patients with
rteriovenous fistula that have a continuous murmur should
e evaluated with CMR (Class I, Level of Evidence: C). In
atients with congenital heart disease, CMR is useful for
valuating patients with suspected pulmonary hypertension
Class I, Level of Evidence: C) and patients with tetralogy of
allot (Class I, Level of Evidence: C). CMR is also recom-
ended to evaluate the great arteries and veins in patients
ith prior atrial baffle procedures (Class I, Level of Evidence:
) and congenitally corrected transposition of the great arteries
Class I, Level of Evidence: C) and managing patients with
omplex congenital heart disease (Class I, Level of Evidence: C).
inally, CMR is reasonable in patients with arterial switch
perations to evaluate the anatomy and hemodynamics in more
etail (Class IIa, Level of Evidence: C) (271).
In addition, the ACC/AHA 2008 Guidelines for the
anagement of Adults With Congenital Heart Diseasendicates that CMR provides additional noninvasive imag- ing information in any situation in which findings generated
y echocardiography are uncertain. This includes evaluation
f patients with intracardiac communication such as atrial
nd ventricular septal defects (271).
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging indicates that CMR is appropriate to assess com-
lex congenital heart disease including anomalies of the
oronary circulation, great vessels, cardiac chambers, and
alves (97). CMR is particularly useful in this regard in
hildren in which exposure to ionizing radiation is to be
voided.
.10. Pulmonary Angiography
E-MRA may be used in patients with a strong suspi-
ion of pulmonary embolism in whom the results of other
ests are equivocal or for whom iodinated contrast ma-
erial or ionizing radiation are relatively contraindicated
272). The writing committee agrees that data in the
iterature are insufficient to recommend where pulmo-
ary CE-MRA should fit into a diagnostic pathway for
ulmonary embolism.
CMR imaging can be used to assess the pulmonary
rteries for acute and chronic thromboembolic disease,
ulmonary arterial stenoses (as in congenital heart disease),
r acquired pulmonary arterial pathology such as iatrogenic
seudoaneurysms. Pulmonary arterial size in patients with
ulmonary arterial hypertension can also be assessed. Pri-
arily, pulmonary CE-MRA is used with the bolus timed
o opacify the pulmonary arteries at the center of k-space
ata acquisition. Time-resolved contrast-enhanced MRA is
articularly useful for imaging the pulmonary vasculature as
t allows complete separation of the pulmonary and systemic
hases.
.10.1. Pulmonary Emboli
here are few studies regarding the utility of data for
ulmonary CE-MRA for the diagnosis of acute pulmo-
ary embolism (273). Although a few prospective single-
enter studies assessing CE-MRA have been performed
274 –277), no large randomized, controlled, multicenter
rial has been reported. Data from these smaller single-
enter studies, however, are promising, with the sensitiv-
ty for pulmonary CE-MRA to detect pulmonary emboli
anging from 77% to 100% and the specificity ranging
rom 95% to 100%.
Real-time CE-MR pulmonary perfusion methods can be
dded to raise the sensitivity for pulmonary embolism
etection (275,278). Techniques used for this purpose have
lower spatial resolution, which may preclude direct visu-
lization of emboli; however, these methods display seg-
ental and subsegmental perfusion defects analogous to
uclear medicine techniques, which can then be used to
ndirectly predict the presence of embolus.
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June 8, 2010:2614–62 Expert Consensus on Cardiovascular Magnetic ResonanceThe Gd-based MR contrast agent administered for
ulmonary CE-MRA can potentially be used to passively
pacify the veins of the pelvis and lower extremities to
rovide information about deep venous thrombosis dur-
ng the same examination. The addition of lower extrem-
ty venous imaging, especially from the femoral veins to
he popliteals, has the potential to increase the overall
ensitivity for pulmonary thromboembolic disease (279).
xperience with MRA, even without the use of a CMR
ontrast agent, for the detection of proximal deep venous
hrombosis and extension into the pelvic veins has shown
sensitivity of 94% to 100% and a specificity of 90% to
00% (280 –282).
.10.2. Summary of Existing Guidelines and
ppropriate Use Criteria
t present, the writing committee recognizes that there are
o guidelines or appropriate use criteria highlighting the
tility of CMR for assessment of pulmonary artery diseases
xclusive of congenital heart disease.
.11. Atrial Fibrillation
MR may be used for assessing left atrial structure and
unction in patients with atrial fibrillation. The writing
ommittee recognizes that evolving techniques utilizing
GE may have high utility for identifying evidence of
brotic tissue within the atrial wall or an adjoining
tructure. Standardization of protocols and further stud-
es are needed to determine if CMR provides a reliable
ffective method for detecting thrombi in the left atrial
ppendage in patients with atrial fibrillation. CMR may
e useful for identifying pulmonary vein anatomy prior to
r after electrophysiology procedures without need for
atient exposure to ionizing radiation.
When assessing patients with atrial fibrillation, CMR
an be used to determine the size and shape of the left
trium and to determine pulmonary vein orientation in
atients receiving surgical or percutaneous ablation to
ontrol heart rate and rhythm. As with determinations of
V and RV chamber size and volumes, CMR has been
sed to characterize left atrial chamber dimensions and
olumes (81,283–289).
.11.1. Preablation Planning
reprocedural CMR can provide the 3D orientation of the
ulmonary vein and atrium for the purpose of reducing the
ime necessary to locate ablation sites during the procedure.
mportant considerations include the presence of atrial
hrombus and variations of pulmonary venous anatomy
290). Most of the required planning and follow-up infor-
ation may be obtained with a CE-MRA (291–293).
MR may prove to be useful for guiding ablation proce-
ures (294,295). Time-resolved MRA is the method of
hoice for assessing the pulmonary veins. For “at-risk”
atients, where Gd administration is undesirable, noncon-
rast MRA using 3D SSFP is a useful alternative. iPulmonary vein stenosis is a potential complication of
blation by pulmonary vein isolation with an incidence
anging from 1.5% to 42% depending on how stenosis is
efined and on the imaging method (296–299). Uncom-
only, pulmonary vein occlusion may lead to pulmonary
nfarction. CMR can be used to identify pulmonary infarc-
ion (300,301).
There are also emerging data to suggest that CMR may
ave a role in determining postablation scar formation in
atients with atrial fibrillation. In this strategy, LGE
echniques are employed to outline the extent of scarred
trial myocardium after ablation. Acquiring a stack of
mages encompassing the atrium allows for the determina-
ion of scar volume (302).
.11.2. Potential Advantages of CMR Relative to
ther Imaging Modalities
t present, the role of CMR in management pathways for
iagnosing left atrial or atrial appendage thrombus (303) is
ot defined. Further studies are required to determine the
linical role of CMR in identifying left atrial thrombi (304).
n centers with expertise, CMR provides an accurate
ethod to obtain pulmonary vein orientation without ex-
osure to ionizing radiation or iodinated contrast.
.11.3. Summary of Existing Guidelines and
ppropriate Use Criteria
t present the writing committee recognizes that there are
o guidelines established for the use of CMR in assessing
atients with atrial fibrillation.
The ACCF/ACR/SCCT/SCMR/ASNC/NASCI/
CAI/SIR 2006 Appropriateness Criteria for Cardiac
omputed Tomography and Cardiac Magnetic Resonance
maging indicates that CMR is an appropriate test to
valuate pulmonary veins prior to radiofrequency ablation
or atrial fibrillation and to identify left atrial and pulmonary
enous anatomy including dimensions of veins for mapping
urposes (97).
.12. Peripheral Arterial Disease
MR for peripheral arterial disease (PAD) may be used
o diagnose anatomic location and degree of stenosis and
s useful in selecting patients with lower extremity PAD
ho are candidates for intervention. Additionally, MRA
f the lower extremities is appropriate for patients with
laudication (305).
PAD has been estimated to affect more than 5 million
dults in the United States (306). CMR provides a nonin-
asive method to evaluate peripheral vessels and to identify
he location and severity of PAD. Proper vascular evaluation
f PAD requires illustration from at least the aortic bifur-
ation through the distal trifurcation vessels (and pedal arch
n cases of limb-threatening ischemia). This imaging re-
q
s
a
fl
s
T
C
w
h
M
p
C
t
f
p
t
s
3
(
(
d
c
i
w
(
b
3
O
I
t
s
l
s
e
t
a
l
M
i
r
d
(
p
p
c
c
C
c
a
i
C
a
g
T
2
C
2 , cardi
T
A
N
g
K
g
2
2642 Hundley et al. JACC Vol. 55, No. 23, 2010
Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62uirement results principally from the high incidence of
ynchronous and tandem lesions.
Several CMR techniques have evolved over time for the
ssessment of peripheral arterial disease, notably 2D time of
ight (TOF) (72,307,308), and 3D CE-MRA (72). The
trengths and limitations of the techniques are shown in
able 7.
Two meta-analyses of the diagnostic performance of
E-MRA for lower extremity arterial evaluation in patients
ith suspected or known PAD (Table 8) demonstrated
eightened accuracy of CE-MRA over noncontrast 2D
RA for detecting and grading the severity of stenoses in
atients with PAD.
The current preferred method for performing peripheral
E-MRA is a multistation (“bolus chase”) 3D CE-MRA
hat provides an extended field of view coverage (e.g., 1 m)
or a single contrast media injection (309–311). For im-
roved visualization of the distal extremity (i.e., infrapopli-
eal and/or pedal) arteries, the bolus chase MRA can be
upplemented by a dedicated separate contrast-enhanced
D MRA using traditional timed arterial-phase CE-MRA
312) or multiphase, time-resolved CE-MRA methods
313,314). The supplement of bolus chase MRA with
edicated distal lower extremity MRA (Figure 15), also
alled “the hybrid” technique (312), has the advantage of
mproved arterial depiction of the infrapopliteal arteries in
hich arterial enhancement can often be variable or fast
diabetic patients [315]), and suboptimally depicted using
olus chase MRA alone (316).
able 7. Peripheral CMR: 2D Time of Flight and Contrast-Enhan
Technique Strengths
D TOF ● No intravenous contrast media requirement
E-MRA (i.e., bolus chase
CE-MRA with time-
resolved CE-MRA)
● Short examination times
● Provides consistently high vascular contrast-to-no
depiction of arterial segments and stenoses
● Less susceptible to flow-related artifacts
● Provides dynamic assessment of vascular territo
D indicates 2-dimensional; CE-MRA, contrast-enhanced magnetic resonance angiography; CMR
able 8. Meta-Analysis of Contrast-Enhanced Magnetic Resona
ngiography for Assessment of Peripheral Arterial Disease
Meta-Analysis Study (Reference) Technique No. of Patient
elemans et al. (2000) (71)
old standard  DSA
CE-MRA 2 patients/10
2D TOF MRA 344 patients/1
oelemay et al. (2001) (70)
old standard  DSA
CE-MRA† 495 patients/1
2D TOF or
2D proximal
compression MRA
679 patients/2D indicates 2-dimensional; CE-MRA, contrast-enhanced magnetic resonance angiography; DSA, digita
*In some studies, patients underwent both CE-MRA and noncontrast 2D MRA. †Single study on 20.12.1. Potential Advantages of CMR Relative to
ther Imaging Modalities
n prospective studies comparing color duplex ultrasound
o peripheral CE-MRA, CE-MRA was found to be more
ensitive and more specific for the detection of arterial
uminal narrowings of greater than 50% (317). A pro-
pective multicenter trial of patients (318) randomized to
ither CE-MRA or duplex ultrasound for PAD evalua-
ion found the results of both studied to have similar
bility to predict changes in disease severity and quality of
ife. Importantly, patients that received peripheral CE-
RA experienced a reduction of additional vascular
maging procedures by 42%.
In a prospective study of consecutive patients (319)
andomized to either peripheral CE-MRA or 16-
etector row cardiac computed tomographic angiography
CTA), CTA was found to be less expensive ($438 per
atient) but with no statistically significant differences in
atient outcomes (i.e., quality of life). Mean therapeutic
onfidence for CE-MRA and CTA were similar and
omparable to that for digital subtraction angiography.
TA exposed participants to ionizing radiation and ionic
ontrast.
A final consideration for comparison of CMR to CTA
nd ultrasound relates to the utility of CMR for character-
zing the components of atherosclerotic plaques (Figure 16).
MR is able to differentiate proton spin characteristics
ssociated with water, fibrosis, and fat, and thereby distin-
uish lipid relative to non-lipid plaque components.
Magnetic Resonance Angiography
Limitations
● Long examination times (greater than 2 hours)
● Highly susceptible to flow-related artifacts that may
result in the overestimation of stenoses or
erroneously mimic arterial occlusion
tio for reliable
ime-resolved CE-MRA)
● Requires intravenous contrast media
administration
ovascular magnetic resonance; and TOF, time of flight.
Angiography Versus Noncontrast 2D Magnetic Resonance
Studies* Sensitivity (%) Specificity (%) Diagnostic Odds Ratio
s 92–100 91–99 7.5
dies 64–100 68–96 4.5
dies 83–100 64–100 2.8
dies 69–100 23–100 1.0ced
ise ra
ries (tnce
s and
studie
3 stu
7 stu
0 stul subtraction angiography; MRA, magnetic resonance angiography; and TOF, time of flight.
subjects evaluated 2D CE-MRA.
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ppropriate Use Criteria
he ACC/AHA 2005 Practice Guidelines for the Manage-
ent of Patients With Peripheral Arterial Disease recom-
ends MRA of the extremities: 1) as useful to diagnose
natomic location and degree of stenosis of PAD (Class I,
evel of Evidence: A); 2) should be performed with Gd
nhancement (Class I, Level of Evidence: B); and 3) useful in
electing patients with lower extremity PAD as candidates
or endovascular intervention (Class I, Level of Evidence: A).
he guidelines also indicate that MRA of the extremities
ay be considered: 1) to select patients with lower extremity
AD as candidates for surgical bypass and to select the sites
f surgical anastomosis (Class IIb, Level of Evidence: B); and
) for post-revascularization (endovascular and surgical
ypass) surveillance in patients with lower extremity PAD
Class IIb, Level of Evidence: B) (305).
In regard to the presentation of claudication, the Amer-
can College of Radiology Appropriateness Criteria 2005
anks MRA of the lower extremities as highly appropriate
ith a ranking of 8 on a scale from 1 (least appropriate) to
(most appropriate) for patients with claudication (320).
.13. Carotid Arterial Disease
MR may be used for defining the location and extent of
arotid arterial stenoses.
Arterial stenosis, occlusion, dissection, or aneurysm may
ccur anywhere from the aortic arch to the intracranial
irculation, in 1 or several sites. Current recommendations
tate that endarterectomy, when performed in the presence
f severe and symptomatic stenosis (i.e., 70% to 99%), can
e expected to prevent 1 stroke in 10 cases performed (321).
s with peripheral angiography, MRA has in recent years
ade considerable advances for the study of the carotid and
ertebrobasilar circulation. Various implementations of 2D
r 3D TOF MRA with or without CE-MRA have met
ith intense interest for rapid, flow-independent evaluation
f the extracranial carotids (322) and vertebrobasilar circu-
ation (323). CE-MRA, however, is demanding machine
ardware to generate sufficiently high spatial resolution
uring the first pass of a contrast agent, and some results in
he intracranial circulation were disappointing (324).
With the more recent dissemination of 3.0-T CMR units
nd the development of multichannel radiofrequency (RF)
ubsystems that support parallel imaging, the performance
f CE-MRA in the carotids has been greatly improved such
hat it rivals CTA and conventional angiography for assess-
ent of carotid stenosis (325) and intracranial aneurysms
326,327) with a significant degree of intermodality agree-
ent between MRA and both CTA and digital subtraction
ngiography (325).
A unique attribute of CMR is the ability to quantify
lood flow. CMR allows for reproducible quantification of
arotid arterial flow, using PC cine imaging. This techniqueigure 15. Bolus Chase Contrast-Enhanced Magnetic Resonance
ngiography
olus chase CE-MRA of the aorta and lower extremity arteries obtained with a
–stage table-stepping protocol during infusion of 0.2 mM/kg of gadolinium chelate
n a patient with peripheral arterial disease. There is evidence of sequential moder-
te stenoses in the left superficial femoral artery (upper arrow), as well as runoff
isease in the left calf (lower arrow). CE-MRA indicates contrast-enhanced magneticas previously been shown to represent a reliable estimation
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ification of the immediate poststenotic region may be of
alue in the determination of peak blood velocity through
his stenosis, an indicator of the hemodynamic significance
f the luminal compromise seen. PC-CMR may also be used
o assess vertebral artery flow in subclavian steal syndrome.
CMR can be used to address certain questions about
laque composition (330,331). However, at the time of
riting, imaging of plaque remains a focus of research, not
et having found a defined role in clinical decision making.
.13.1. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR provides the capability to visualize carotid arterial
egments and the intracranial carotid system, the vertebro-
asilar system, and the aortic arch—important for the
dentification of coexistent or primary disease. This is
ccomplished noninvasively, without exposure to ionizing
adiation. During the same examination, quantitative flow
easurements may be acquired.
.13.2. Summary of Existing Guidelines and
ppropriate Use Criteria
he writing committee recognizes that few guidelines or
ppropriate use criteria are available for the use of CMR for
ssessing the carotid arteries.
.14. CMR of Thoracic Aortic Disease
MR may be used for defining the location and extent of
ortic aneurysms, erosions, ulcers, dissections; evaluating
ost-surgical processes involving the aorta and surround-
ng structures, and aortic size blood flow and cardiac
ycle–dependent changes in area.
CMR imaging techniques (e.g., spin echo, GRE, and
ine PC; and 3D CE-MRA) permit the assessment of both
he characteristic anatomic abnormalities and the predispos-
ng or resulting pathophysiologic changes (332–335) asso-
iated with diseases of the aorta, including: aortic diameters,
ortic root visualization, supra-aortic branch assessment,
nd recognition of aortic pathologies (e.g., aneurysm, com-
unicating dissection, ulcers, noncommunicating dissec-
ion) (336). If surgical repair for thoracic aortic disease has
igure 16. Atherosclerotic Plaques in Cardiovascular Magnetic Re
ultispectral atherosclerotic plaque imaging of the SFA in the same patient as Figur
ight. The lumen is preserved (long white arrows), yet there is significant atheroscler
onsistent with calcification (seen on all 3 image weightings). The large white arrowh
ipid-rich necrotic core. The brighter areas around the lumen on PDW and T2-W imag
ral artery; T1-W, T1-weighted; and T2-W, T2-weighted.een performed, CE-MRA can be used to assess progres-ion or regression of the responsible disease process or
etection of complications of the surgery (e.g., graft infec-
ion) (332,337–339). The utility of CMR for providing
nformation regarding diseases of the aorta is provided in
able 9.
.14.1. Potential Advantages of CMR Relative to
ther Imaging Modalities
MR can visualize the arterial lumen, assess the aortic wall,
nd measure flow in the aorta without ionizing radiation.
.14.2. Summary of Existing Guidelines and
ppropriate Use Criteria
he writing committee recognizes that few guidelines or
ppropriate use criteria are available for the use of CMR for
ssessing the aorta.
.15. Renal Arterial Disease
MR may be used for evaluating renal arterial stenoses
nd quantifying renal arterial blood flow.
able 9. Cardiovascular Magnetic Resonance of Thoracic
ortic Diseases
Disease of Aorta
Unique Contributions of
Cardiovascular Magnetic Resonance (Reference)
therosclerosis and
penetrating ulcer
● Identify aortic wall pseudoaneurysm,
noncommunicating dissection, aortic rupture
(340–342)
neurysm ● Etiology (e.g., atherosclerosis, annuloaortic ectasia)
(332–334)
● Assess associated changes in aortic valve (i.e.,
regurgitation) (343)
● Presurgical planning and postsurgical follow-up
raumatic injury ● Identify hemorrhage within aortic wall
● Differentiate partial versus circumferential tears
issection ● Identify acute versus chronic
● Locate entry and exit flaps and extent of dissection
● Measure flow in true and false lumen
● Identify and assess severity of aortic valve
pathology (344,345)
● Differentiate intramural hematoma (323,346,347)
ortitis ● Measure aortic wall thickness in response to
treatment
● Detection of wall inflammation (348–350)
nce
ith a T1-W image on the left, PDW image in the middle, and T2-W image on the
aque in the wall. The black arrows on the T1-W image point to areas of low signal
point to areas of low signal on the PDW and T2-W images that are consistent with
resent fibrous tissue. PDW indicates proton density–weighted; SFA, superficial fem-sona
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rterial disease (any condition which results in irregularity,
tenosis, dissection, or aneurysmal dilatation of the renal
rteries). Specifically, CMR can be used to determine the
ollowing:
. The number and location of renal arteries. Multiple renal
arteries are common and occur in approximately 24% of
cases with bilateral multiple renal arteries in 5% of the
population (351).
. The severity of renal artery stenosis, including the
presence of fibromuscular dysplasia.
. The configuration of the renal blood supply. The inci-
dence of horseshoe kidney at necropsy is estimated at
1:666 (352). Furthermore, only in 30% of cases is the
horseshoe kidney supplied by a single renal artery to each
side, the majority of cases receiving multiple renal
arteries bilaterally, as well as variable arterial supply of
the midline isthmus (353).
. The presence of renal or adrenal parenchymal mass
lesions.
Recent studies have estimated the sensitivity and speci-
city of 3.0-T MRA in the detection of intra-abdominal
rterial stenosis as 100% and greater than 92%, respectively
354,355).
.15.1. Potential Advantages of CMR Relative to
ther Imaging Modalities
he absence of associated ionizing radiation and nonio-
inated contrast medium injection reduces potential tox-
cities related to ionic contrast materials, particularly in
atients with renal insufficiency (356). CMR offers the
pportunity to perform both morphological renal arterial
ssessment as well as derive complementary flow-related
ata by means of PC flow quantification of individual
enal arteries. This combined approach to renal imaging
ay provide insight into which patients would most
enefit from endovascular intervention (357,358). In
ddition to high-resolution 3D large field-of-view data
cquisition, renal arterial MRA also allows assessment of
he renal and adrenal parenchymal tissue for the presence
f congenital anomalies or potentially causative occult
umors. Time-resolved first-pass perfusion imaging of
he kidneys may be valuable in identifying significant
enovascular lesions (359).
.15.2. Summary of Existing Guidelines and
ppropriate Use Criteria
he writing committee recognizes that few guidelines for
ppropriate use criteria are available for the use of CMR
or assessing the renal arteries. The ACC/AHA 2005
ractice Guidelines for the Management of Patients
ith Peripheral Arterial Disease (lower extremity, renal,
esenteric, and abdominal aortic) designates CMR a
lass I recommendation as a screening test to establish che diagnosis of renal arterial stenosis (Level of Evidence: B)
305).
. CMR Safety
.1. Introduction
MR is generally considered safe, but there are important
afety concerns that fall into 3 general categories: potential
rojectiles in the MR scanner room, implanted cardiovas-
ular devices, and issues related to contrast administration.
n regard to potential projectiles, it is important to remem-
er that the magnet is always “on.” Therefore, ferromagnetic
aterials entering the MR room are a hazard and can be
rawn into the bore of the scanner with unopposable and
nstoppable force. This produces an immediate lethal dan-
er to anyone in the scanner or in the path of ferromagnetic
aterial attracted to the scanner bore. For this reason, local
uidelines and safety policies are developed to guard against
erromagnetic material entering the MR environment.
This section will explore the issues related to implanted
evices and MR contrast and present an overview of the
ypes of devices that are of concern, as well as the underlying
afety considerations for patients with these devices. Since
evice specifications change frequently, a comprehensive list
f CMR compatible or incompatible devices is not possible,
nd information on specific devices will need to be obtained
ither from the manufacturer’s package inserts or CMR
afety Web sites or handbooks. After reviewing devices,
ssues related to Gd contrast will be presented.
.2. General Safety Considerations for
mplanted Devices
here are several reasons that implanted devices may pose
afety considerations for patients undergoing CMR. First,
he CMR scanner generates a very powerful static magnetic
eld. Ferromagnetic objects (i.e., those that contain iron)
ill interact with the static field and may move in the
atient’s body. Nearly all implanted devices, however, are
onferromagnetic or only weakly ferromagnetic. Each de-
ice must undergo separate testing to determine whether it
s likely to translate or rotate in the magnetic field. Besides
he static magnetic field, additional smaller and changing
agnetic fields, termed gradients, are generated during
MR scanning. These gradient fields may change very
apidly during CMR scanning. Gradient fields can produce
lectric currents in wires or leads that can potentially result
n arrhythmia.
In addition to magnetic fields, radiofrequency waves are
ransmitted into the patient by the CMR scanner. These
adiofrequency waves are absorbed by the body and can
roduce slight (less than 1°C) heating of the patient. With
espect to implanted devices, these radiowaves may poten-
ially interfere with certain electronic components as well as
ause heating at the tips of implanted wires.
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Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62Besides the type of devices, there are many variables that
ffect the likelihood that a CMR device could be affected by
he CMR scanner. These include the location of the device,
he strength of the CMR scanner and, potentially, whether
he device has been acutely placed or is firmly fixed in
osition. Because of these factors, experts in CMR safety
nd physics should be consulted when presented with an
nfamiliar device prior to undergoing CMR. This applies to
ndividuals with implanted devices receiving any type of
agnetic resonance procedure including the heart, brain,
xtremities, or other body/organ/structure/part. If the type
f device is unknown, alternatives to performing CMR
hould be evaluated. In general, the benefits of undergoing
MR must be weighed against the potential risk of injury to
he patient or device failure.
Prior to undergoing CMR, patients are screened for both
mplanted cardiovascular devices as well as other types of
mplants. Patients are screened by licensed MR technolo-
ists with supervision by a CMR-knowledgeable physician.
tandardized screen forms are available (360–362) that
hould be completed prior to undergoing CMR.
Medical devices are classified by the American Society for
esting and Materials as “MR safe,” “MR conditional,” and
MR unsafe” (Table 10) (363).
.3. CMR Scanning Post Device Implantation
evices that are manufactured from nonferromagnetic ma-
erial (300 series stainless steel, titanium, titanium alloy,
itinol) that have no electrical or magnetic components and
hat have no concern for heating due to CMR may undergo
MR scanning immediately after implantation.
For devices that are weakly ferromagnetic, CMR safety has
ot been established for every device, and in some cases, the
MR scanner could potentially dislodge or move such a device
mmediately after implantation. Devices that are firmly im-
lanted into a vessel wall or adjacent tissues are less likely to
ndergo motion. In the case of heart values in particular, the
orces of the heart on the valve are often much greater than the
MR forces due to weak ferromagnetism. In general, waiting
fter implantation (e.g., for 6 weeks) may be considered if this
s an option for the patient. For weakly ferromagnetic devices,
he risks and benefits of CMR immediately after implantation
eed to be considered to determine whether it is necessary or
able 10. Safety Terminology for Implanted Devices
R safe A device that poses no hazards in the
MR environment.
R conditional A device that poses no known hazards in a specific
MR imaging environment with constraints on the
conditions of use. These constraints may
include, e.g., the magnetic field strength or
specific absorption rate.
R unsafe An item that is known to pose hazards in all
MR environments.
R indicates magnetic resonance.ossible to defer the CMR scan. a.4. Coronary Artery and Peripheral Vascular Stents
ost coronary artery and peripheral vascular stents exhibit
eak ferromagnetism or are nonferromagnetic. Anchoring
n the vascular wall likely provides protection against move-
ent, and further anchoring of the stent may occur due to
issue ingrowth at 6 to 8 weeks after implantation. However,
or nonferromagnetic coronary stents, there is no good
ationale or clinical data to suggest that a delay is necessary
fter implantation. Data on specific coronary stents suggest
hat many of these could be considered CMR safe (364–367)
ut not necessarily at the highest (3.0-T) magnetic fields
366,368,369). There have been no reports of increased risk
f stent subacute or late thrombosis following CMR scans
367,370–373).
Drug-eluting stents have the same considerations as
onventional stents regarding ferromagnetism (374). Slight
eating of the stent (less than 1°C or less than 2°C for
verlapping stents) has been reported, but the effect of this
n the drug-eluting properties of the stent is unknown. It is
ossible that stent heating may be mitigated by a heat-sink
ffect of flowing blood in the vessel. A small study of
atients after myocardial infarction who underwent MR
ithin 2 weeks of stent implantation detected no increased
ncidence of adverse events at 30 days and 6-month
ollow-up compared with patients who did not undergo
MR (375).
.5. Aortic Stent Grafts
ost aortic stent grafts that have been tested have been
abeled as MR safe with the exception of the Zenith AAA
ndovascular Graft Stent, which has been labeled as MR
nsafe (362,376). The Zenith stent has significant deflec-
ion and torque of the stainless steel component of the graft
n the magnetic field. Although no adverse events have been
eported with the Zenith stent, there remains a potential for
evice migration or vessel damage so that the risks and
enefits of CMR examination should be considered in these
atients (377). With other aortic stent grafts (e.g., End-
logic AAA or Lifepath AA), there may be significant
ssociated artifact around the stent or obscuring of the
ascular lumen due to the metallic components.
.6. Intracardiac Devices
he majority of prosthetic heart valves and annuloplasty
ings that have been tested have been labeled as MR
afe, with a lesser number labeled as MR conditional. In
eneral, the presence of a prosthetic heart valve or annulo-
lasty ring is not considered a contraindication to CMR
xamination up to 3.0-T at any time after implantation
376,378–382). The forces exerted on valve prosthesis are
ubstantially less than those exerted by the beating heart and
ulsatile flow (383). The forces required to pull a suture
hrough the valve annulus tissue have been shown to be
reater than magnetically induced forces up to a field
trength of 4.7-T (384). Thus, patients with valve prosthesis
re unlikely to be at risk for valve dehiscence during clinical
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een determined to be less than 1°C in ex vivo studies
378,380,381,385,386); this is likely to be less due to the
eat-sink effect of flowing blood. Valve dysfunction due to
nteraction with the magnetic field has not been reported.
Cardiac closure and left atrial appendage occluder devices
re either weakly ferromagnetic or nonferromagnetic depend-
ng on the materials used (376,387,388). The majority of
ardiac closure and occluder devices that have been tested have
een labeled as MR safe; several that have been tested are
abeled as MR conditional (362). Patients with nonferromag-
etic cardiac closure and occluder devices may undergo CMR
rocedures at any time after implantation. The timing of CMR
xamination at 3.0-T or less in patients with cardiac closure or
ccluder devices that are weakly ferromagnetic should be
eighed on a case-by-case basis. For cases in which there is a
lear potential clinical benefit of scanning in the days to weeks
fter implantation, the benefits of the MR examination will
ikely outweigh the risks of the examination.
Sternal wires associated with cardiac surgery/valve re-
lacement are not considered to be a contraindication to
MR examination.
.7. Inferior Vena Cava Filters
MR examinations of both animals and humans with
mplanted inferior vena cava (IVC) filters have thus far not
eported complications or symptomatic filter displacement
389–394). Most IVC filters that have been tested have
een labeled as MR safe; the remainder of IVC filters that
ave been tested are classified as MR conditional (362). In
atients who have a weakly ferromagnetic IVC filter (Gi-
nturco bird nest IVC filter [Cook, Bloomington, Ind],
tainless steel Greenfield vena cava filter [Boston Scientific,
atertown, Mass]), consideration should be made to wait
t least 6 weeks before performing CMR examination to
llow firm implantation of the device. In cases where there
s a strong clinical indication for CMR and the device is
rmly anchored, the benefits of performing the CMR prior
o 6 weeks may outweigh the potential risks.
.8. Embolization Coils
ommonly utilized embolization coils are either nonferro-
agnetic or weakly ferromagnetic. Although there is theo-
etical potential for coil heating during a CMR examina-
ion, no significant effects were found on the Guglielmi
etachable coil (GDC) (Boston Scientific) ex vivo (395) or
n patient studies (396). Embolization coils made from
itinol, platinum, or platinum and iridium have been
valuated and found to be safe for CMR performed at
agnetic field strengths of 3.0-T or less (376,397–400).
latinum coils implanted in the CNS have not been
eported to cause complications for patients undergoing
R. Most embolization coils that have been tested have
een labeled as MR safe; the remainder of embolization
oils that have been tested have been labeled as MR
onditional (362). For weakly ferromagnetic devices, the tisks of performing CMR prior to 6 weeks after coil
lacement must be considered relative to the benefits of
MR on a case-by-case basis.
.9. Hemodynamic Monitoring and
emporary Pacing Devices
etained temporary epicardial pacing leads are relatively
hort in length without large loops. These are felt not to
ose a significant risk during CMR. No complications have
een reported as a result of MR scanning for a patient with
etained leads (401).
Hemodynamic catheters that contain conducting wires
nd those few temporary transvenous pacing wires that
ave been tested have been labeled as MR unsafe (362).
atients with pulmonary artery hemodynamic monitoring/
hermodilution catheters (such as the Swan-Ganz catheter)
hould not undergo CMR examinations because of the
ossible associated risks unless labeling information or
nstructions for use are provided that permit CMR exami-
ations to be performed safely. Nonferromagnetic pulmo-
ary artery catheters without electrically conductive path-
ays in the catheter are safe for CMR examination.
CMR of patients with temporary pacemaker external
ulse generators is not recommended as CMR can alter the
peration of an external pulse generator or damage it.
acing of the patient during the CMR may also be
nreliable with a temporary transvenous lead.
.10. Permanent Cardiac Pacemakers and
mplantable Cardioverter Defibrillators
ue to the wide prevalence of cardiovascular diseases, a
ignificant proportion of patients who would normally be
eferred for CMR examinations will have permanent cardiac
acemakers or implantable cardioverter defibrillators
ICDs). Pacemakers and ICDs contain metal with ferro-
agnetic properties, as well as complex electrical systems
ith 1 or several leads implanted into the myocardium.
otential complications of CMR under these circumstances
nclude damage or movement of the device, inhibition of the
acing output, activation of the tachyarrhythmia therapy of
he device, cardiac stimulation, and heating of the electrode
ips (402–408). These factors may lead to clinical sequelae
ncluding changes in pacing/defibrillation thresholds, pace-
aker ICD dysfunction or damage (including battery de-
letion), arrhythmia, or death (404,409,410).
A few small clinical trials have been conducted to assess
onditions under which MR examination with these devices
ould be conducted safely. Pacemaker-dependent patients
ere excluded from these studies, and the heart rhythm was
onitored during the exam. No episodes of pacing above
he upper rate limit or arrhythmias were noted (410),
hough 1 patient had a change in device programming
411). Another study suggested that ICDs and pacemakers
anufactured after the year 2000 are more resistant to the
lectrical and magnetic fields associated with MR examina-
ion at 1.5-T (412). To date, it is likely that several hundred
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Expert Consensus on Cardiovascular Magnetic Resonance June 8, 2010:2614–62atients have undergone MR examination with either pace-
akers or ICDs (413–419), and strategies and protocols for
afe pacemaker/ICD scanning during CMR have been
roposed (420,421). As of this writing, no deaths have been
eported under conditions in which patients were deliber-
tely scanned and monitored during the MR examination,
lthough changes in pacing threshold, programming
hanges, need for device reprogramming, and possibly
attery depletion have been reported.
Currently, pacemakers available in the United States
re labeled as MR unsafe (362). At present, CMR
xamination of patients with pacemakers is discouraged
nd should only be considered at highly experienced
enters in cases in which there is a strong clinical
ndication and where the benefits clearly outweigh the
isks. CMR examination of patients with ICDs should
ot be performed unless the center is highly experienced
n both the operation of these devices and in complex
MR procedures in the setting of highly compelling
ircumstances where the benefits clearly outweigh the
isks.
.11. Retained Transvenous Pacemaker and
efibrillator Leads
here are no clinical studies that have specifically addressed
he risk for CMR associated with retained pacemaker or
CD leads. Since no radiofrequency chokes are present on
hese leads, significant heating of the lead tips may occur.
MR in these circumstances is discouraged, and CMR
xamination should only be considered in centers with
xpertise in electrophysiology and CMR when there are no
lternatives to the CMR examination under compelling
linical circumstances. Similarly, CMR examination should
ot be performed in patients with known retained trans-
enous leads that have fractures.
.12. Hemodynamic Support Devices
emodynamic support devices such as ventricular assist
evices and intra-aortic balloon pumps are complex
lectromagnetic devices containing ferromagnetic mate-
ials. Formal CMR testing of these devices has not been
onducted. However, it is believed that these hemody-
amic support devices represent absolute contraindica-
ions to CMR examination.
.13. Gadolinium Contrast Agents
adolinium contrast agents are frequently used for CE-
RA as well as for imaging the heart for LGE, perfu-
ion, or masses. Currently the use of Gd contrast agents
or these purposes is off-label in the United States. Unlike
odinated contrast materials used with radiographic tech-
iques, there are different safety issues relating to under-
ying renal function that need to be considered prior to
heir administration.
Mild-to-moderate reactions to Gd contrast agents
e.g., hives, shortness of breath) have been reported to cccur in approximately 1 in 5000 patients. Severe ana-
hylactic reactions occur in 1 in 250 000 to 300 000
atients. Nephrogenic systemic fibrosis (NSF) is an
xtremely rare but important complication of Gd admin-
stration associated with acute renal failure or severe renal
ailure due to advanced chronic kidney disease (National
idney Foundation Stage 4 or 5 renal failure). NSF is a
cleroderma-like fibrosing entity of the skin (422). The
isease has systemic features that include involvement of
leura, pericardium, lungs, joints, and striated muscle
including diaphragm and myocardium) (359,423). Be-
ides acute renal failure or severe renal failure due to
dvanced chronic kidney disease (glomerular filtration
ate less than 30 mL/min/1.73 m2), other characteristics
hat have been implicated with an increased risk for NSF
nclude severe liver failure or liver transplant, kidney
ransplant, hypercoagulability, deep vein thrombosis, and
issue injury secondary to surgical procedures (424). The
-year incidence of NSF in the presence of all recognized
isk factors (end-stage renal disease [ESRD], use of Gd
ontrast, dialysis, and proinflammatory events) has been
stimated to be between 1% (unpublished data, Mayo
linic Experience; ISMRM proceedings, Toronto, 2008)
nd 4.6% (425). Over 200 cases have been reported to the
ood and Drug Administration as of May 2007, but not
ll are confirmed. Given the total number of Gd contrast
pplications, the overall risk of NSF in other groups is
onsidered very low. Because of the risk of NSF, screen-
ng for reduced renal function prior to CMR should be
onsidered in most individuals and particularly in at-risk
roups, for example, older patients, individuals with
istory of renal disease or dysfunction, or patients with a
rior renal transplant. Patients with hepatorenal syn-
rome in association with severe liver disease, periliver
ransplant patients, and patients with acute renal failure
re typically poor candidates for Gd contrast administra-
ion. Patients undergoing peritoneal dialysis have pro-
onged retention of Gd contrast agents and their use is
iscouraged. The use of Gd in patients with ESRD must
e balanced by the significant risk of NSF (3% to 5%).
nce informed consent is obtained, using a macrocyclic
helate (like gadoteridol) in the lowest possible dose and
voiding repeat exposure appear reasonable measures,
ased on available evidence (426). Postprocedure hemo-
ialysis of all patients with ESRD should be considered.
. Summary
ith its advantages in studying patients with cardiovascular
isease and ability to provide high-resolution images, CMR
ffers a suitable mechanism for assessment in various clinical
nd research applications. Table 11 summarizes the writing
ommittee’s potential indications for the use of CMR in
linical practice situations.
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Disease/Condition Recommendations for Use in Clinical Practice
eart failure CMRmay be used for assessment of LV and RV size and morphology, systolic and diastolic function, and for characterizing myocardial
tissue for the purpose of understanding the etiology of LV systolic or diastolic dysfunction. The writing committee recognizes the
potential capabilities of spectroscopic techniques for acquiring metabolic information of the heart when evaluating individuals with
heart failure.
oronary artery disease CMRmay be used for identifying coronary artery anomalies and aneurysms and for determining coronary artery patency. In specialized
centers, CMRmay be uniquely useful in identifying patients with multivessel coronary artery disease without exposure to ionizing
radiation or iodinated contrast medium.
schemic heart disease The combination of CMR stress perfusion, function, and LGE allows the use of CMR as a primary form of testing for
● identifying patients with ischemic heart disease when there are resting ECG abnormalities or an inability to exercise,
● defining patients with large vessel coronary artery disease and its distribution who are candidates for interventional
procedures, or
● determining patients who are appropriate candidates for interventional procedures.
Assessment of LV wall motion after low-dose dobutamine in patients with resting akinetic LV wall segments is useful for identifying
patients who will develop improvement in LV systolic function after coronary arterial revascularization. The writing committee
recognizes the potential advantages of spectroscopic techniques for identifying early evidence of myocardial ischemia that may or may
not be evident using existing non-CMRmethods.
yocardial infarction/scar LGE-CMRmay be used for identifying the extent and location of myocardial necrosis in individuals suspected of having or possessing
chronic or acute ischemic heart disease.
onischemic cardiomyopathy/
myocarditis
CMRmay be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to
ischemic heart disease. When the diagnosis is unclear, CMRmay be considered to identify the etiology of cardiac dysfunction in
patients presenting with heart failure including
● evaluation of dilated cardiomyopathy in the setting of normal coronary arteries,
● patients with positive cardiac enzymes without obstructive atherosclerosis on angiography,
● patients suspected of amyloidosis or other infiltrative diseases,
● hypertrophic cardiomyopathy,
● arrhythmogenic right ventricular dysplasia, or
● syncope or ventricular arrhythmia.
ssessment of valvular heart
disease
CMRmay be used for assessing individuals with valvular heart disease in which evaluation of valvular stenosis, regurgitation, para- or
perivalvular masses, perivalvular complications of infectious processes, or prosthetic valve disease are needed. CMRmay be useful in
identifying serial changes in LV volumes or mass in patients with valvular dysfunction.
ardiac masses CMRmay be used for clinical evaluation of cardiac masses, extracardiac structures, and involvement and characterization of masses in
the differentiation of tumors from thrombi.
ericardial disease (constrictive
pericarditis)
CMRmay be used as a noninvasive imaging modality to diagnose patients with suspected pericardial disease. CMR can provide a
comprehensive structural and functional assessment of the pericardium as well as evaluate the physiological consequences of
pericardial constriction.
ongenital heart disease CMRmay be used for assessing cardiac structure and function, blood flow, and cardiac and extracardiac conduits in individuals with
simple and complex congenital heart disease. Specifically, CMR can be used to identify and characterize congenital heart disease, to
assess the magnitude or quantify the severity of intracardiac shunts or extracardiac conduit blood flow to evaluate the aorta, and to
assess the pathological and physiologic consequences of congenital heart disease on left and right atrial and ventricular function and
anatomy.
ulmonary angiography CE-MRAmay be used in patients with a strong suspicion of pulmonary embolism in whom the results of other tests are equivocal or for
whom iodinated contrast material or ionizing radiation are relatively contraindicated (255). The writing committee agrees that data in
the literature are insufficient to recommend where pulmonary CE-MRA should fit into a diagnostic pathway for pulmonary embolism.
trial fibrillation CMRmay be used for assessing left atrial structure and function in patients with atrial fibrillation. The writing committee recognizes that
evolving techniques utilizing LGEmay have high utility for identifying evidence of fibrotic tissue within the atrial wall or an adjoining
structure. Standardization of protocols and further studies are needed to determine if CMR provides a reliable effective method for
detecting thrombi in the left atrial appendage in patients with atrial fibrillation. CMR is recommended for identifying pulmonary vein
anatomy prior to or after electrophysiology procedures without need for patient exposure to ionizing radiation.
eripheral arterial disease CMR recommendations for PAD are in agreement with current guidelines and appropriate use criteria.
CMR for PAD
1. is recommended to diagnose anatomic location and degree of stenosis of PAD (Class I, Level of Evidence: A);
2. should be performed with gadolinium enhancement (Class I, Level of Evidence: B); and
3. is useful in selecting patients with lower extremity PAD as candidates for endovascular intervention (Class I,
Level of Evidence: A).
CMR of the extremities may be considered
1. to select patients with lower extremity PAD as candidates for surgical bypass and to select the sites of surgical anastomosis
(Class IIb, Level of Evidence: B); and
2. for post-revascularization (endovascular and surgical bypass) surveillance in patients with lower extremity PAD (Class IIb,
Level of Evidence: B) (288).
Additionally, MRA of the lower extremities is appropriate for patients with claudication.
arotid arterial disease CMRmay be used for defining the location and extent of carotid arterial stenoses.
MR of thoracic aortic disease CMRmay be used for defining the location and extent of aortic aneurysms, erosions, ulcers, dissections; evaluating postsurgical
processes involving the aorta and surrounding structures, and aortic size blood flow and cardiac cycle–dependent changes in area.
enal arterial disease CMRmay be used for evaluating renal arterial stenoses and quantifying renal arterial blood flow.E-MRA indicates contrast-enhanced magnetic resonance angiography; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular; RV,
ight ventricular; MRA, magnetic resonance angiography; and PAD, peripheral arterial disease.
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